CN110590806B - 含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物及其制备方法和用途 - Google Patents
含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物及其制备方法和用途 Download PDFInfo
- Publication number
- CN110590806B CN110590806B CN201910925935.3A CN201910925935A CN110590806B CN 110590806 B CN110590806 B CN 110590806B CN 201910925935 A CN201910925935 A CN 201910925935A CN 110590806 B CN110590806 B CN 110590806B
- Authority
- CN
- China
- Prior art keywords
- thieno
- methyl
- pyrimidin
- oxo
- acryloyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 150000001788 chalcone derivatives Chemical class 0.000 title claims abstract 11
- -1 thieno [2,3-d ] pyrimidine-2-yl Chemical group 0.000 title claims description 33
- 150000001875 compounds Chemical class 0.000 claims abstract description 110
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 55
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 17
- 230000000259 anti-tumor effect Effects 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- IOZWTNNVPCLNQS-VOTSOKGWSA-N 2-[(E)-3-(4-bromophenyl)-3-oxoprop-1-enyl]-6-methyl-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound BrC1=CC=C(C=C1)C(/C=C/C=1NC(C2=C(N=1)SC(=C2)C)=O)=O IOZWTNNVPCLNQS-VOTSOKGWSA-N 0.000 claims description 5
- JYRNCBDKVCGQQI-QPJJXVBHSA-N 2-[(E)-3-(4-bromophenyl)prop-2-enoyl]-6-methyl-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound BrC1=CC=C(C=C1)/C=C/C(=O)C=1NC(C2=C(N=1)SC(=C2)C)=O JYRNCBDKVCGQQI-QPJJXVBHSA-N 0.000 claims description 5
- JRGLONFIKNLPJX-VOTSOKGWSA-N 2-[(E)-3-(4-fluorophenyl)-3-oxoprop-1-enyl]-6-methyl-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound FC1=CC=C(C=C1)C(/C=C/C=1NC(C2=C(N=1)SC(=C2)C)=O)=O JRGLONFIKNLPJX-VOTSOKGWSA-N 0.000 claims description 5
- JLXNMACOODBNKE-VOTSOKGWSA-N 6-methyl-2-[(E)-3-(4-nitrophenyl)-3-oxoprop-1-enyl]-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound CC1=CC2=C(N=C(NC2=O)\C=C\C(=O)C2=CC=C(C=C2)[N+](=O)[O-])S1 JLXNMACOODBNKE-VOTSOKGWSA-N 0.000 claims description 5
- LOFFQCFTGRYXJH-AATRIKPKSA-N 6-methyl-2-[(E)-3-oxo-3-pyridin-2-ylprop-1-enyl]-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound CC1=CC2=C(N=C(NC2=O)\C=C\C(C2=NC=CC=C2)=O)S1 LOFFQCFTGRYXJH-AATRIKPKSA-N 0.000 claims description 5
- WJNWZOKETVFTQR-SNAWJCMRSA-N 6-methyl-2-[(E)-3-oxo-3-pyridin-3-ylprop-1-enyl]-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound CC1=CC2=C(N=C(NC2=O)\C=C\C(C=2C=NC=CC=2)=O)S1 WJNWZOKETVFTQR-SNAWJCMRSA-N 0.000 claims description 5
- WCIGWDCZXPJLAR-AATRIKPKSA-N 6-methyl-2-[(E)-3-pyridin-2-ylprop-2-enoyl]-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound CC1=CC2=C(N=C(NC2=O)C(\C=C\C2=NC=CC=C2)=O)S1 WCIGWDCZXPJLAR-AATRIKPKSA-N 0.000 claims description 5
- MOKANQJRAFMCRV-SNAWJCMRSA-N 6-methyl-2-[(E)-3-pyridin-3-ylprop-2-enoyl]-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound CC1=CC2=C(N=C(NC2=O)C(\C=C\C=2C=NC=CC=2)=O)S1 MOKANQJRAFMCRV-SNAWJCMRSA-N 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- 125000005808 2,4,6-trimethoxyphenyl group Chemical group [H][#6]-1=[#6](-[#8]C([H])([H])[H])-[#6](-*)=[#6](-[#8]C([H])([H])[H])-[#6]([H])=[#6]-1-[#8]C([H])([H])[H] 0.000 claims description 4
- BYSZXTMMJQOQHE-VOTSOKGWSA-N 2-[(E)-3-(2,4-dimethoxyphenyl)-3-oxoprop-1-enyl]-6-methyl-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound COC1=C(C=CC(=C1)OC)C(/C=C/C=1NC(C2=C(N=1)SC(=C2)C)=O)=O BYSZXTMMJQOQHE-VOTSOKGWSA-N 0.000 claims description 4
- RKCDDPIPVWNIGJ-FNORWQNLSA-N 2-[(E)-3-(2,4-dimethoxyphenyl)prop-2-enoyl]-6-methyl-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound COC1=C(C=CC(=C1)OC)/C=C/C(=O)C=1NC(C2=C(N=1)SC(=C2)C)=O RKCDDPIPVWNIGJ-FNORWQNLSA-N 0.000 claims description 4
- FYXKKUPTZJXJQK-QPJJXVBHSA-N 2-[(E)-3-(4-fluorophenyl)prop-2-enoyl]-6-methyl-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound FC1=CC=C(C=C1)/C=C/C(=O)C=1NC(C2=C(N=1)SC(=C2)C)=O FYXKKUPTZJXJQK-QPJJXVBHSA-N 0.000 claims description 4
- DCTZSAVUAVALFC-AATRIKPKSA-N 2-[(E)-3-(4-hydroxy-3-methoxyphenyl)-3-oxoprop-1-enyl]-6-methyl-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound OC1=C(C=C(C=C1)C(/C=C/C=1NC(C2=C(N=1)SC(=C2)C)=O)=O)OC DCTZSAVUAVALFC-AATRIKPKSA-N 0.000 claims description 4
- IWWMMTRMGILSSC-GQCTYLIASA-N 2-[(E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]-6-methyl-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound OC1=C(C=C(C=C1)/C=C/C(=O)C=1NC(C2=C(N=1)SC(=C2)C)=O)OC IWWMMTRMGILSSC-GQCTYLIASA-N 0.000 claims description 4
- VOWGMFLXRTVMRO-BQYQJAHWSA-N 2-[(E)-3-(4-methoxyphenyl)-3-oxoprop-1-enyl]-6-methyl-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound COC1=CC=C(C=C1)C(/C=C/C=1NC(C2=C(N=1)SC(=C2)C)=O)=O VOWGMFLXRTVMRO-BQYQJAHWSA-N 0.000 claims description 4
- ZFWRXUVQOZIAKW-VMPITWQZSA-N 2-[(E)-3-(4-methoxyphenyl)prop-2-enoyl]-6-methyl-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound COC1=CC=C(C=C1)/C=C/C(=O)C=1NC(C2=C(N=1)SC(=C2)C)=O ZFWRXUVQOZIAKW-VMPITWQZSA-N 0.000 claims description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 4
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 4
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 4
- IFOUURRLFSKRIZ-AATRIKPKSA-N 6-methyl-2-[(E)-3-(2,4,6-trimethoxyphenyl)prop-2-enoyl]-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound CC1=CC2=C(N=C(NC2=O)C(\C=C\C2=C(C=C(C=C2OC)OC)OC)=O)S1 IFOUURRLFSKRIZ-AATRIKPKSA-N 0.000 claims description 4
- VZUDUBFNFWLBRY-AATRIKPKSA-N 6-methyl-2-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound CC1=CC2=C(N=C(NC2=O)C(\C=C\C2=CC(=C(C(=C2)OC)OC)OC)=O)S1 VZUDUBFNFWLBRY-AATRIKPKSA-N 0.000 claims description 4
- SEPUNVAIODJRGS-QPJJXVBHSA-N 6-methyl-2-[(E)-3-(4-nitrophenyl)prop-2-enoyl]-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound CC1=CC2=C(N=C(NC2=O)C(\C=C\C2=CC=C(C=C2)[N+](=O)[O-])=O)S1 SEPUNVAIODJRGS-QPJJXVBHSA-N 0.000 claims description 4
- ICRNVIMBBWCVRK-AATRIKPKSA-N 6-methyl-2-[(E)-3-oxo-3-(2,4,6-trimethoxyphenyl)prop-1-enyl]-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound COC1=C(C(=CC(=C1)OC)OC)C(/C=C/C=1NC(C2=C(N=1)SC(=C2)C)=O)=O ICRNVIMBBWCVRK-AATRIKPKSA-N 0.000 claims description 4
- LLENJWUOBDZAOK-AATRIKPKSA-N 6-methyl-2-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)prop-1-enyl]-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound COC=1C=C(C=C(C=1OC)OC)C(/C=C/C=1NC(C2=C(N=1)SC(=C2)C)=O)=O LLENJWUOBDZAOK-AATRIKPKSA-N 0.000 claims description 4
- ICUCQDADJGOXBU-BQYQJAHWSA-N 6-methyl-2-[(E)-3-oxo-3-phenylprop-1-enyl]-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound CC1=CC2=C(N=C(NC2=O)\C=C\C(C2=CC=CC=C2)=O)S1 ICUCQDADJGOXBU-BQYQJAHWSA-N 0.000 claims description 4
- WOZWQGUCYXTYOI-NSCUHMNNSA-N 6-methyl-2-[(E)-3-oxo-3-pyridin-4-ylprop-1-enyl]-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound CC1=CC2=C(N=C(NC2=O)\C=C\C(C2=CC=NC=C2)=O)S1 WOZWQGUCYXTYOI-NSCUHMNNSA-N 0.000 claims description 4
- LFOMZCQXMYCROE-NSCUHMNNSA-N 6-methyl-2-[(E)-3-pyridin-4-ylprop-2-enoyl]-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound CC1=CC2=C(N=C(NC2=O)C(\C=C\C2=CC=NC=C2)=O)S1 LFOMZCQXMYCROE-NSCUHMNNSA-N 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- YVSOJBZWCDGAOI-VOTSOKGWSA-N 2-[(E)-3-(4-chlorophenyl)-3-oxoprop-1-enyl]-6-methyl-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound ClC1=CC=C(C=C1)C(/C=C/C=1NC(C2=C(N=1)SC(=C2)C)=O)=O YVSOJBZWCDGAOI-VOTSOKGWSA-N 0.000 claims description 3
- DTPUYLRSQONBFU-QPJJXVBHSA-N 2-[(E)-3-(4-chlorophenyl)prop-2-enoyl]-6-methyl-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound ClC1=CC=C(C=C1)/C=C/C(=O)C=1NC(C2=C(N=1)SC(=C2)C)=O DTPUYLRSQONBFU-QPJJXVBHSA-N 0.000 claims description 3
- DNMWIBOJAVLLMW-SNAWJCMRSA-N 2-[(E)-3-(furan-2-yl)-3-oxoprop-1-enyl]-6-methyl-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound O1C(=CC=C1)C(/C=C/C=1NC(C2=C(N=1)SC(=C2)C)=O)=O DNMWIBOJAVLLMW-SNAWJCMRSA-N 0.000 claims description 3
- GGDWQSRWAMDAIV-SNAWJCMRSA-N 2-[(E)-3-(furan-2-yl)prop-2-enoyl]-6-methyl-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound O1C(=CC=C1)/C=C/C(=O)C=1NC(C2=C(N=1)SC(=C2)C)=O GGDWQSRWAMDAIV-SNAWJCMRSA-N 0.000 claims description 3
- QQGCQAFOZLYNIR-BQYQJAHWSA-N 6-methyl-2-[(E)-3-(4-methylphenyl)-3-oxoprop-1-enyl]-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound CC1=CC=C(C=C1)C(/C=C/C=1NC(C2=C(N=1)SC(=C2)C)=O)=O QQGCQAFOZLYNIR-BQYQJAHWSA-N 0.000 claims description 3
- AYLBKMFSWXXEJF-BQYQJAHWSA-N 6-methyl-2-[(E)-3-(4-methylphenyl)prop-2-enoyl]-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound CC1=CC=C(C=C1)/C=C/C(=O)C=1NC(C2=C(N=1)SC(=C2)C)=O AYLBKMFSWXXEJF-BQYQJAHWSA-N 0.000 claims description 3
- HFQCZRGXQRLGPS-SNAWJCMRSA-N 6-methyl-2-[(E)-3-oxo-3-thiophen-2-ylprop-1-enyl]-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound CC1=CC2=C(N=C(NC2=O)\C=C\C(C=2SC=CC=2)=O)S1 HFQCZRGXQRLGPS-SNAWJCMRSA-N 0.000 claims description 3
- GZJAWRKJOTVVCM-SNAWJCMRSA-N 6-methyl-2-[(E)-3-thiophen-2-ylprop-2-enoyl]-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound CC1=CC2=C(N=C(NC2=O)C(\C=C\C=2SC=CC=2)=O)S1 GZJAWRKJOTVVCM-SNAWJCMRSA-N 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 230000005764 inhibitory process Effects 0.000 abstract description 8
- 206010006187 Breast cancer Diseases 0.000 abstract description 6
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 6
- 206010009944 Colon cancer Diseases 0.000 abstract description 6
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 6
- 206010008342 Cervix carcinoma Diseases 0.000 abstract description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract description 5
- 201000010881 cervical cancer Diseases 0.000 abstract description 5
- 201000007270 liver cancer Diseases 0.000 abstract description 5
- 208000014018 liver neoplasm Diseases 0.000 abstract description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 4
- 201000005202 lung cancer Diseases 0.000 abstract description 4
- 208000020816 lung neoplasm Diseases 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Substances [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 116
- 210000004027 cell Anatomy 0.000 description 48
- 239000007787 solid Substances 0.000 description 48
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 41
- 238000005160 1H NMR spectroscopy Methods 0.000 description 39
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 34
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 33
- 150000001789 chalcones Chemical class 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 13
- DTQVDTLACAAQTR-DYCDLGHISA-N trifluoroacetic acid-d1 Chemical compound [2H]OC(=O)C(F)(F)F DTQVDTLACAAQTR-DYCDLGHISA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 230000001472 cytotoxic effect Effects 0.000 description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 108010022394 Threonine synthase Proteins 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 235000005513 chalcones Nutrition 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000002390 rotary evaporation Methods 0.000 description 7
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 229930192474 thiophene Natural products 0.000 description 6
- 102000005497 Thymidylate Synthase Human genes 0.000 description 5
- 230000001028 anti-proliverative effect Effects 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzenecarboxaldehyde Natural products O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 5
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 102000004243 Tubulin Human genes 0.000 description 4
- 108090000704 Tubulin Proteins 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 4
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000004052 folic acid antagonist Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 150000003230 pyrimidines Chemical class 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Natural products CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 3
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 description 3
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Substances CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 102000004419 dihydrofolate reductase Human genes 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 230000006618 mitotic catastrophe Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HPJGEESDHAUUQR-SKGSPYGFSA-N (2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[(2s)-3-naphthalen-2-yl-2-(3-pyridin-3-ylpropanoylamino)propanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]buta Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)CCC=1C=NC=CC=1)CC1=CC=CC=C1 HPJGEESDHAUUQR-SKGSPYGFSA-N 0.000 description 2
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- LUBJCRLGQSPQNN-UHFFFAOYSA-N 1-Phenylurea Chemical compound NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 description 2
- CRBZVDLXAIFERF-UHFFFAOYSA-N 2,4,6-trimethoxybenzaldehyde Chemical compound COC1=CC(OC)=C(C=O)C(OC)=C1 CRBZVDLXAIFERF-UHFFFAOYSA-N 0.000 description 2
- LWRSYTXEQUUTKW-UHFFFAOYSA-N 2,4-dimethoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(OC)=C1 LWRSYTXEQUUTKW-UHFFFAOYSA-N 0.000 description 2
- DVGHAYAFIHAXOR-UHFFFAOYSA-N 2-amino-5-methylthiophene-3-carboxamide Chemical compound CC1=CC(C(N)=O)=C(N)S1 DVGHAYAFIHAXOR-UHFFFAOYSA-N 0.000 description 2
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 2
- OPHQOIGEOHXOGX-UHFFFAOYSA-N 3,4,5-trimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1OC OPHQOIGEOHXOGX-UHFFFAOYSA-N 0.000 description 2
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 2
- NTPLXRHDUXRPNE-UHFFFAOYSA-N 4-methoxyacetophenone Chemical compound COC1=CC=C(C(C)=O)C=C1 NTPLXRHDUXRPNE-UHFFFAOYSA-N 0.000 description 2
- LJNDDAHMJWHKER-UHFFFAOYSA-N 6-methyl-4-oxo-3H-thieno[2,3-d]pyrimidine-2-carbaldehyde Chemical compound CC1=CC2=C(N=C(NC2=O)C=O)S1 LJNDDAHMJWHKER-UHFFFAOYSA-N 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- 102100029855 Caspase-3 Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 230000004668 G2/M phase Effects 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 150000008062 acetophenones Chemical class 0.000 description 2
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 230000003432 anti-folate effect Effects 0.000 description 2
- 229940127074 antifolate Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 2
- 238000002737 cell proliferation kit Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- AYBUNZGJQVYGTM-UHFFFAOYSA-N ethyl 2-amino-5-methylthiophene-3-carboxylate Chemical compound CCOC(=O)C=1C=C(C)SC=1N AYBUNZGJQVYGTM-UHFFFAOYSA-N 0.000 description 2
- ANCBHJKEYPZCTE-UHFFFAOYSA-N ethyl 5-carbamoyl-4-methyl-2-[(2,3,4,5,6-pentafluorobenzoyl)amino]thiophene-3-carboxylate Chemical compound CC1=C(C(N)=O)SC(NC(=O)C=2C(=C(F)C(F)=C(F)C=2F)F)=C1C(=O)OCC ANCBHJKEYPZCTE-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BGXZIBSLBRKDTP-UHFFFAOYSA-N methyl 9-(4-chloroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Cl)C=C1 BGXZIBSLBRKDTP-UHFFFAOYSA-N 0.000 description 2
- KQNYTTDHCMFOME-UHFFFAOYSA-N methyl n-[[3-[(4-tert-butylpiperazin-1-yl)methyl]-8-fluoro-2-phenylquinoline-4-carbonyl]amino]-n-phenylcarbamate Chemical compound C=1C=CC=CC=1N(C(=O)OC)NC(=O)C(C1=CC=CC(F)=C1N=C1C=2C=CC=CC=2)=C1CN1CCN(C(C)(C)C)CC1 KQNYTTDHCMFOME-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- DDWBRNXDKNIQDY-UHFFFAOYSA-N thieno[2,3-d]pyrimidine Chemical class N1=CN=C2SC=CC2=C1 DDWBRNXDKNIQDY-UHFFFAOYSA-N 0.000 description 2
- 150000003672 ureas Chemical class 0.000 description 2
- DIXMBHMNEHPFCX-MCMMXHMISA-N (2r)-2-[5-[6-amino-5-[(1r)-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]pyridin-3-yl]-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol Chemical compound O([C@H](C)C=1C(=CC=C(F)C=1)N1N=CC=N1)C(C(=NC=1)N)=CC=1C=1SC([C@](C)(O)CO)=NC=1C DIXMBHMNEHPFCX-MCMMXHMISA-N 0.000 description 1
- KRIWIRSMQRQYJG-DLBZAZTESA-N (2s,3s)-3-[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]butane-1,2,4-triol Chemical compound C=1C(N[C@@H](CO)[C@H](O)CO)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1 KRIWIRSMQRQYJG-DLBZAZTESA-N 0.000 description 1
- LPNRUMVKXCLEBE-JXVRESAISA-L (3r)-4-[[(e)-2-[5-ethyl-4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethenyl]-oxidophosphoryl]-3-hydroxybutanoate Chemical compound CCC1=C(C=2C=CC=CC=2)N=C(C(C)C)C(\C=C\P([O-])(=O)C[C@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 LPNRUMVKXCLEBE-JXVRESAISA-L 0.000 description 1
- DMQYDVBIPXAAJA-VHXPQNKSSA-N (3z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)-(5-methyl-1h-imidazol-2-yl)methylidene]-1h-indol-2-one Chemical compound C1CN(CC)CCC1NC1=CC=C(NC(=O)\C2=C(/C=3NC=C(C)N=3)C=3C=C(F)C=CC=3)C2=C1 DMQYDVBIPXAAJA-VHXPQNKSSA-N 0.000 description 1
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 1
- QVBVQHTXLPNXEY-ZMFCMNQTSA-N (4r)-6-[2-[4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(C(C)C)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 QVBVQHTXLPNXEY-ZMFCMNQTSA-N 0.000 description 1
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- QOLHWXNSCZGWHK-BWBORTOCSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecylcarbamoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)NCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QOLHWXNSCZGWHK-BWBORTOCSA-N 0.000 description 1
- CRUILBNAQILVHZ-UHFFFAOYSA-N 1,2,3-trimethoxybenzene Chemical group COC1=CC=CC(OC)=C1OC CRUILBNAQILVHZ-UHFFFAOYSA-N 0.000 description 1
- KPZWHZSIXZXDMW-UHFFFAOYSA-N 1-(2,4,6-trimethoxyphenyl)ethanone Chemical compound COC1=CC(OC)=C(C(C)=O)C(OC)=C1 KPZWHZSIXZXDMW-UHFFFAOYSA-N 0.000 description 1
- WYECURVXVYPVAT-UHFFFAOYSA-N 1-(4-bromophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Br)C=C1 WYECURVXVYPVAT-UHFFFAOYSA-N 0.000 description 1
- BUZYGTVTZYSBCU-UHFFFAOYSA-N 1-(4-chlorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C=C1 BUZYGTVTZYSBCU-UHFFFAOYSA-N 0.000 description 1
- ZDPAWHACYDRYIW-UHFFFAOYSA-N 1-(4-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=C1 ZDPAWHACYDRYIW-UHFFFAOYSA-N 0.000 description 1
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 1
- SAXKWTPDZMBKSQ-UHFFFAOYSA-N 2,2-dimethylchromene Chemical compound C1=CC=C2C=CC(C)(C)OC2=C1 SAXKWTPDZMBKSQ-UHFFFAOYSA-N 0.000 description 1
- VQTDPCRSXHFMOL-UHFFFAOYSA-N 2,4-Dimethoxyacetophenone Chemical compound COC1=CC=C(C(C)=O)C(OC)=C1 VQTDPCRSXHFMOL-UHFFFAOYSA-N 0.000 description 1
- MXAYFCHUXRRPQJ-UHFFFAOYSA-N 2-(chloromethyl)-6-methyl-3h-thieno[2,3-d]pyrimidin-4-one Chemical compound S1C(C)=CC2=C1N=C(CCl)NC2=O MXAYFCHUXRRPQJ-UHFFFAOYSA-N 0.000 description 1
- NZSUAJMEMUTEQE-UHFFFAOYSA-N 2-[2-[3-(4-sulfophenyl)-1H-tetrazol-2-yl]phenoxy]acetic acid Chemical compound C1=CC=C(C(=C1)N2NC=NN2C3=CC=C(C=C3)S(=O)(=O)O)OCC(=O)O NZSUAJMEMUTEQE-UHFFFAOYSA-N 0.000 description 1
- NOJBEJIBTCCLFC-UHFFFAOYSA-N 2-acetyl-6-methyl-3H-thieno[2,3-d]pyrimidin-4-one Chemical compound O=C1NC(C(=O)C)=NC2=C1C=C(C)S2 NOJBEJIBTCCLFC-UHFFFAOYSA-N 0.000 description 1
- AUUTXOKCFQTKPL-UHFFFAOYSA-N 2-oxopropanoyl chloride Chemical compound CC(=O)C(Cl)=O AUUTXOKCFQTKPL-UHFFFAOYSA-N 0.000 description 1
- VUGQIIQFXCXZJU-UHFFFAOYSA-N 3,4,5-trimethoxyacetophenone Chemical compound COC1=CC(C(C)=O)=CC(OC)=C1OC VUGQIIQFXCXZJU-UHFFFAOYSA-N 0.000 description 1
- YLLRPQWLASQXSI-UHFFFAOYSA-N 3-(4b,8a,9,9a-tetrahydro-4aH-pyrido[2,3-b]indol-4-ylamino)phenol Chemical compound Oc1cccc(NC2=CC=NC3NC4C=CC=CC4C23)c1 YLLRPQWLASQXSI-UHFFFAOYSA-N 0.000 description 1
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- YQYGPGKTNQNXMH-UHFFFAOYSA-N 4-nitroacetophenone Chemical compound CC(=O)C1=CC=C([N+]([O-])=O)C=C1 YQYGPGKTNQNXMH-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 229940126559 Compound 4e Drugs 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- FULZLIGZKMKICU-UHFFFAOYSA-N N-phenylthiourea Chemical compound NC(=S)NC1=CC=CC=C1 FULZLIGZKMKICU-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- DFYRUELUNQRZTB-UHFFFAOYSA-N apocynin Chemical compound COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 229940125872 compound 4d Drugs 0.000 description 1
- 229940126115 compound 4f Drugs 0.000 description 1
- 229940125880 compound 4j Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- YWKVMGDEOUPQGN-UHFFFAOYSA-N ethyl 2-[4-[2-(3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl)ethynyl]phenyl]acetate Chemical compound C1=CC(CC(=O)OCC)=CC=C1C#CC1(O)C(CC2)CCN2C1 YWKVMGDEOUPQGN-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 125000004387 flavanoid group Chemical group 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 210000004293 human mammary gland Anatomy 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 125000004388 isoflavanoid group Chemical group 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000006667 mitochondrial pathway Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- PHHRKRGXWSEXFZ-UHFFFAOYSA-N n-(pyridin-3-ylmethyl)-3-[[2-[(2,3,4-trifluorophenoxy)methyl]-1,3-benzoxazol-4-yl]oxy]propan-1-amine Chemical compound FC1=C(F)C(F)=CC=C1OCC(OC1=CC=C2)=NC1=C2OCCCNCC1=CC=CN=C1 PHHRKRGXWSEXFZ-UHFFFAOYSA-N 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- DOWVMJFBDGWVML-UHFFFAOYSA-N n-cyclohexyl-n-methyl-4-(1-oxidopyridin-1-ium-3-yl)imidazole-1-carboxamide Chemical compound C1=NC(C=2C=[N+]([O-])C=CC=2)=CN1C(=O)N(C)C1CCCCC1 DOWVMJFBDGWVML-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 229940023144 sodium glycolate Drugs 0.000 description 1
- 230000024355 spindle assembly checkpoint Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 239000003734 thymidylate synthase inhibitor Substances 0.000 description 1
- DKZBBWMURDFHNE-UHFFFAOYSA-N trans-coniferylaldehyde Natural products COC1=CC(C=CC=O)=CC=C1O DKZBBWMURDFHNE-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003733 xanthohumol Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
本发明公开了含噻吩并[2,3‑d]嘧啶‑2‑基的查耳酮类似物，如通式(I)所示，其中，各取代基的定义详见说明书。此外，还公开了上述化合物的制备方法。该通式(I)所示的化合物不仅对人乳腺癌(MFC‑7和MDA‑MB‑231)、人宫颈癌(HeLa)、人结肠癌(HCT‑116和HT‑29)和人肺癌细胞株(A549)细胞的增殖具有抑制作用，而且对人肝癌细胞株(HepG2)的增殖具有抑制作用，可用作抗肿瘤药物。
Description
技术领域
本发明涉及药物化学领域，更具体地说涉及含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物，及其制备方法和它们在抗肿瘤药物中的应用。
背景技术
噻吩并[2,3-d]嘧啶是一个重要的杂环母体，其衍生物在抗肿瘤药物研究中引起了广泛的关注(Aly,A.A.；Ishak,E.A.；Ramadan,M.；Germoush,M.O.；El-Emary,T.I.；Al-Muaikel,N.S.Recent report on thieno[2,3-d]pyrimidines.Their preparationincluding microwave and their utilities in fused heterocycles synthesis.J.Heterocycl.Chem.2013,50,451-472)。在噻吩并[2,3-d]嘧啶的C5或C6位引入侧链，所得衍生物具有叶酸拮抗剂的作用及抗肿瘤活性。例如，Gangjee等合成了在C5位连有L-谷氨酸残基或者疏水性侧链的噻吩并[2,3-d]嘧啶衍生物，并测试了它们作为抗叶酸剂的抗肿瘤活性(Gangjee,A.；Li,W.；Kisliuk,R.L.；Cody,V.；Pace,J.；Piraino,J.；Makin,J.Design,synthesis,and X-ray crystal structure of classical and nonclassical2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylatesynthase and dihydrofolate reductase inhibitors and as potential antitumoragents.J.Med.Chem.2009,52,4892-902)。其中，经典抗叶酸剂I对二氢叶酸还原酶(dihydrofolate reductase，DHFR)和胸苷酸合成酶(thymidylate synthase，TS)的抑制活性较好，IC50值分别为54、19nM，且对人白血病、非小细胞肺癌、黑色素瘤、卵巢癌、肾癌等8种细胞的GI50值均在10nM以下。用芳胺、杂环胺等基团修饰噻吩并[2,3-d]嘧啶的C4位，可得到蛋白激酶抑制剂。Abdelhaleem等将苯基脲或苯基硫脲结构片段与噻吩并[2,3-d]嘧啶的C4位相连接，合成了一系列噻吩并[2,3-d]嘧啶的脲衍生物，其中活性最好的化合物II对MCF-7细胞活性最好(IC50＝7.10μM)，而且其细胞毒活性与拓扑异构酶II(IC50＝9.29μM)和人血管上皮生长因子受体-2(IC50＝0.2μM)抑制活性有一定的相关性(Abdelhaleem,E.F.；Abdelhameid,M.K.；Kassab,A.E.；Kandeel,M.M.Design and synthesis ofthienopyrimidine urea derivatives with potential cytotoxic and pro-apoptoticactivity against breast cancer cell line MCF-7.Eur.J.Med.Chem.2018,143,1807-1825)。同时，化合物II能够引起细胞周期中subG1和G2/M期的积累，显著提高p53基因的表达，升高Bax/Bcl-2蛋白水平比例，同时激活caspase-3，从而证实了II可通过线粒体通路诱导细胞凋亡。虽然大部分研究都集中在对C-4、C-5和C-6位进行修饰，但越来越多的证据表明，在噻吩并[2,3-d]嘧啶的C2位引入不同的取代基，也能够得到具有良好抗肿瘤活性的化合物。Amawi等将不同取代的苯环与噻吩并[2,3-d]嘧啶的C2位连接，合成了一系列衍生物(Amawi,H.；Karthikeyan,C.；Pathak,R.；Hussein,N.；Christman,R.；Robey,R.；Ashby,C.R.,Jr.；Trivedi,P.；Malhotra,A.；Tiwari,A.K.Thienopyrimidine derivatives exerttheir anticancer efficacy via apoptosis induction,oxidative stress andmitotic catastrophe.Eur.J.Med.Chem.2017,138,1053-1065)。其中，化合物III能够通过诱导细胞凋亡，同时引发有丝分裂灾难(mitotic catastrophe)，从而在5种癌细胞中发挥细胞毒活性。Yang等在噻吩并[2,3-d]嘧啶的C2位引入氨基二硫代甲酸酯，从合成的化合物中筛选出化合物IV，对A549细胞的增殖具有抑制作用(IC50＝4.87μM)，将细胞阻滞在G2/M期并激活纺锤体装配检验点。本课题组进一步设计、合成了化合物IV的生物素化探针，采用生物素-链霉亲和素亲和纯化技术和生物质谱检测，鉴定出IV的靶蛋白为微管蛋白(tubulin)。此外，IV能够抑制体外微管蛋白的聚合，竞争性结合微管蛋白的紫杉醇位点，并对A549细胞紫杉醇耐药株具有抗增殖活性(Yang,C.R.；Peng,B.；Cao,S.L.；Ren,T.T.；Jiang,W.；Wang,F.C.；Li,Y.S.；Li,Z.；Xu,S.；Liao,J.；Wang,H.L.；Li,J.；Xu,X.Synthesis,cytotoxic evaluation and target identification of thieno[2,3-d]pyrimidine derivatives with a dithiocarbamate side chain atC2position.Eur.J.Med.Chem.2018,154,324-340)。
查耳酮(chalcone)是植物中一类重要的次级代谢产物，也是植物体内合成黄酮(flavonoid)及异黄酮(isoflavonoid)的天然前体。天然存在及合成的查耳酮类似物具有广泛的生物活性，包括抗肿瘤活性。查耳酮由两个苯环以及连接苯环的α,β-不饱和羰基体系构成，通常将与羰基相连的苯环称为A环，与碳碳双键相连的称为B环。近年来，研究者将不同的取代基引入查耳酮的A、B环，或用芳杂环代替查耳酮的A、B环，所得查耳酮类似物可通过不同的机制发挥抗肿瘤作用。Zhang等改变查耳酮上的取代基，合成了43个查耳酮类似物，发现化合物V(IC50＝1.4μM in HeLa cells)选择性抑制硫氧还原蛋白还原酶，诱导HeLa细胞产生活性氧(reactive oxygen species,ROS)，促进氧化应激介导的细胞凋亡(Zhang,B.；Duan,D.；Ge,C.；Yao,J.；Liu,Y.；Li,X.；Fang,J.Synthesis of Xanthohumolanalogues and discovery of potent thioredoxin reductase inhibitor aspotential anticancer agent.J.Med.Chem.2015,58,1795-1805)。Yan等以3,4,5-三甲氧基苯环、2,2-二甲基苯并吡喃为A环，分别在吲哚环的C4、C5或C3位上与α,β-不饱和羰基体系连接，合成了大量查耳酮类似物，其中化合物VI对A549、HeLa、7402、MCF-7、A2780和HCT-8细胞的IC50值为3-9nM(Yan,J.；Chen,J.；Zhang,S.；Hu,J.；Huang,L.；Li,X.Synthesis,evaluation,and mechanism study of novel indole-chalcone derivatives exertingeffective antitumor activity through microtubule destabilization in vitro andin vivo.J.Med.Chem.2016,59,5264-83)。VI与微管蛋白的秋水仙碱位点结合，抑制微管蛋白的聚合，将A549细胞阻滞在G2/M期；VI可上调Bax、Bad，下调Bcl-2、Bcl-xl等蛋白水平，诱导细胞凋亡。而且，VI对人乳腺细胞MCF-10A、休眠的人脐静脉血管内皮细胞(quiescentHUVECs)、人皮肤成纤维细胞BJ及人胚肺成纤维细胞HLF等正常细胞系的IC50值比对A549细胞的大100-1000倍，具有较高的选择性。Han等设计、合成了喹唑啉-2-基位分别为A、B环的查耳酮类似物VII、VIII，并测试了细胞毒活性。其中，化合物VIIId(R2＝2',5'-diOCH3C6H3)对HCT-116细胞的IC50值为3.36μM，对细胞周期分布无明显的影响，但sub G1细胞随着浓度提高而出现明显的积累。VIIId引起线粒体膜电位下降，提高cleaved PARP1、cleavedcaspase 3、cleaved caspase 7和cleaved caspase 9等凋亡相关蛋白的水平，诱导HCT-116细胞凋亡(Han,X.；Peng,B.；Xiao,B.B.；Cao,S.L.；Yang,C.R.；Wang,W.Z.；Wang,F.C.；Li,H.Y.；Yuan,X.L.；Shi,R.；Liao,J.；Wang,H.L.；Li,J.；Xu,X.Synthesis andevaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group aspotential anti-tumor agents.Eur.J.Med.Chem.2019,162,586-601)。
噻吩并[2,3-d]嘧啶衍生物(I-V)和查耳酮及其类似物(VII-VIII)的结构。
曹胜利等曾将2-甲基-4-氧代喹唑啉-6-基分别作为A或B环，合成了如下结构的查耳酮的类似物，其对人结肠癌HCT-116和人乳腺癌MCF-7细胞具有抗增殖作用[曹胜利，许兴智，廖蓟，丁盼盼，马丽，张晶晶，唐雪，含2-甲基-4-氧代喹唑啉-6-基的查耳酮类似物及其制备方法和用途，专利申请号CN201510146525.0]。
发明内容
以下是对本文详细描述的主题的概述。本概述并非是为了限制权利要求的保护范围。
本发明人合成了新型的噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物，该化合物具有抗肿瘤活性。
本发明的目的是提供一种含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物。
本发明的另一个目的是提供上述含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物的制备方法。
本发明的另一个目的是提供包含上述含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物的药用组合物。
本发明的另一个目的是提供包含上述含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物在制备抗肿瘤药物中的用途。
在本发明的实施方案中，本发明提供了一种含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物，如通式(I)所示：
其中，式(I)中Ar1和Ar2中的一个为如式(X)所示的噻吩并[2,3-d]嘧啶基，即：
Ar1和Ar2中的另一个为未取代的芳烃基或取代的芳烃基、或者杂芳基；优选地，所述未取代的芳烃基为苯基，所述取代的芳烃基为取代的苯基；所述取代的苯基是指苯环被一个或两个以上的C1-4烷基、任意个卤代C1-4烷基、C1-4烷氧基、C1-4烷氧羰酰基、羟基、卤素、氨基、单C1-4烷基取代的氨基、双C1-4烷基取代的氨基、硝基或氰基所取代，而且在苯环上取代的位置没有限定，或者苯环上相邻的两个碳和与其相连的杂原子、亚烷基一起形成5元或6元杂环，其中杂原子为氮或氧且杂原子个数为2个；更优选地，所述取代的苯基为4-甲基苯基、4-甲氧基苯基、4-硝基苯基、4-溴代苯基、4-氯代苯基、4-氟代苯基、2,4-二甲氧基苯基、4-羟基-3-甲氧基苯基、2,4,6-三甲氧基苯基、或3,4,5-三甲氧基苯基；所述杂芳基为噻吩基、呋喃基、或吡啶基；更优选地，所述杂芳基为噻吩-2-基、呋喃-2-基、吡啶-2-基、吡啶-3-基、或吡啶-4-基；
式(X)中取代基R1和R2各自独立地为氢或者C1-C4烷基(例如甲基、乙基、正丙基、异丙基、正丁基、异丙基、或叔丁基)；优选地，R1为甲基，R2为氢。
在本发明的一些实施方案中，本发明提供的查耳酮类似物，其中，式(I)为下列式(II)化合物：
其中，Ar2为未取代的芳烃基或取代的芳烃基、或者杂芳基；优选地，所述未取代的芳烃基为苯基，所述取代的芳烃基为取代的苯基；所述取代的苯基是指苯环被一个或两个以上的C1-4烷基、任意个卤代C1-4烷基、C1-4烷氧基、C1-4烷氧羰酰基、羟基、卤素、氨基、单C1-4烷基取代的氨基、双C1-4烷基取代的氨基、硝基或氰基所取代，而且在苯环上取代的位置没有限定，或者苯环上相邻的两个碳和与其相连的杂原子、亚烷基一起形成5元或6元杂环，其中杂原子为氮或氧且杂原子个数为2个；更优选地，所述取代的苯基为4-甲基苯基、4-甲氧基苯基、4-硝基苯基、4-溴代苯基、4-氯代苯基、4-氟代苯基、2,4-二甲氧基苯基、4-羟基-3-甲氧基苯基、2,4,6-三甲氧基苯基、或3,4,5-三甲氧基苯基；所述杂芳基为噻吩基、呋喃基、或吡啶基；更优选地，所述杂芳基为噻吩-2-基、呋喃-2-基、吡啶-2-基、吡啶-3-基、或吡啶-4-基；
取代基R1和R2各自独立地为氢或者C1-C4烷基(例如甲基、乙基、正丙基、异丙基、正丁基、异丙基、或叔丁基)；优选地，R1为甲基，R2为氢。
在本发明的一些实施方案中，本发明提供的查耳酮类似物，其中，式(I)为下列式(III)化合物：
其中，Ar1为未取代的芳烃基或取代的芳烃基、或者杂芳基；优选地，所述未取代的芳烃基为苯基，所述取代的芳烃基为取代的苯基；所述取代的苯基是指苯环被一个或两个以上的C1-4烷基、任意个卤代C1-4烷基、C1-4烷氧基、C1-4烷氧羰酰基、羟基、卤素、氨基、单C1-4烷基取代的氨基、双C1-4烷基取代的氨基、硝基或氰基所取代，而且在苯环上取代的位置没有限定，或者苯环上相邻的两个碳和与其相连的杂原子、亚烷基一起形成5元或6元杂环，其中杂原子为氮或氧且杂原子个数为2个；更优选地，所述取代的苯基为4-甲基苯基、4-甲氧基苯基、4-硝基苯基、4-溴代苯基、4-氯代苯基、4-氟代苯基、2,4-二甲氧基苯基、4-羟基-3-甲氧基苯基、2,4,6-三甲氧基苯基、或3,4,5-三甲氧基苯基；所述杂芳基为噻吩基、呋喃基、或吡啶基；更优选地，所述杂芳基为噻吩-2-基、呋喃-2-基、吡啶-2-基、吡啶-3-基、或吡啶-4-基；
取代基R1和R2各自独立地为氢或者C1-C4烷基(例如甲基、乙基、正丙基、异丙基、正丁基、异丙基、或叔丁基)；优选地，R1为甲基，R2为氢。
在本发明的一种实施方案中，本发明提供的一种上述通式(I)化合物，其选自下列化合物：
(E)-6-甲基-2-(3-苯基丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(4a)；
(E)-6-甲基-2-(3-(4-甲氧基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(4b)；
(E)-6-甲基-2-(3-(2,4-二甲氧基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(4c)；
(E)-6-甲基-2-(3-(2,4,6-三甲氧基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(4d)；
(E)-6-甲基-2-(3-(3,4,5-三甲氧基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(4e)；
(E)-6-甲基-2-(3-(4-羟基-3-甲氧基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(4f)；
(E)-6-甲基-2-(3-(4-甲基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(4g)；
(E)-6-甲基-2-(3-(4-溴苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(4h)；
(E)-6-甲基-2-(3-(4-氯苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(4i)；
(E)-6-甲基-2-(3-(4-氟苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(4j)；
(E)-6-甲基-2-(3-(4-硝基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(4k)；
(E)-6-甲基-2-(3-(呋喃-2-基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(4l)；
(E)-6-甲基-2-(3-(噻吩-2-基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(4m)；
(E)-6-甲基-2-(3-(吡啶-2-基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(4n)；
(E)-6-甲基-2-(3-(吡啶-3-基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(4o)；
(E)-6-甲基-2-(3-(吡啶-4-基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(4p)；
(E)-6-甲基-2-(3-氧代-3-苯基丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(8a)；
(E)-6-甲基-2-(3-氧代-3-(4-甲氧基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(8b)；
(E)-6-甲基-2-(3-氧代-3-(2,4-二甲氧基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(8c)；
(E)-6-甲基-2-(3-氧代-3-(2,4,6-三甲氧基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(8d)；
(E)-6-甲基-2-(3-氧代-3-(3,4,5-三甲氧基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(8e)；
(E)-6-甲基-2-(3-氧代-3-(4-羟基-3-甲氧基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(8f)；
(E)-6-甲基-2-(3-氧代-3-(4-甲基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(8g)；
(E)-6-甲基-2-(3-氧代-3-(4-溴苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(8h)；
(E)-6-甲基-2-(3-氧代-3-(4-氯苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(8i)；
(E)-6-甲基-2-(3-氧代-3-(4-氟苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(8j)；
(E)-6-甲基-2-(3-氧代-3-(4-硝基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(8k)；
(E)-6-甲基-2-(3-氧代-3-(呋喃-2-基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(8l)；
(E)-6-甲基-2-(3-氧代-3-(噻吩-2-基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(8m)；
(E)-6-甲基-2-(3-氧代-3-(吡啶-2-基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(8n)；
(E)-6-甲基-2-(3-氧代-3-(吡啶-3-基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(8o)；或
(E)-6-甲基-2-(3-氧代-3-(吡啶-4-基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(8p)。
另一方面，本发明提供了如通式(I)所示含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物的制备方法，当Ar1为式(X)，即为本发明提供的式(I)为式(II)化合物，包括如下步骤：
中间体(IV)与式(VI)化合物在碱性条件下反应，得到式(II)化合物；
式(II)化合物、式(IV)化合物和式(VI)化合物中的取代基，Ar2、R1和R2的定义如式(I)化合物；
或者，
当Ar2为式(X)，即为本发明提供的式(I)为式(III)化合物，包括如下步骤：
中间体(V)与式(VII)化合物在碱性条件下反应，得到式(III)化合物：
式(III)化合物、式(V)化合物和式(VII)化合物中的取代基，Ar1、R1和R2的定义如式(I)化合物。
在本发明提供的如通式(I)所示含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物的制备方法中，其中，所述碱性条件是指在无机碱、有机碱存在下，在水或有机溶剂中，或水和有机溶剂的混合液中反应，例如采用氢氧化钾，在甲醇中反应。
在本发明提供的如通式(I)所示含4-氧代喹唑啉-2-基的查耳酮类似物的制备方法中，其中，中间体IV可以通过如下路线合成：
首先，以三乙胺为碱，将式(IX)化合物(当R1为甲基，R2为氢时为丙醛)、氰乙酰胺及单质硫在乙醇中50-55℃反应4h，生成式(XI)化合物。将丙酮酸与二氯亚砜在三氯甲烷中回流反应0.5h，生成丙酮酰氯；将式(XI)化合物与丙酮酰氯在四氢呋喃中回流反应2h，生成式(VIII)化合物。式(VIII)化合物在碱存在下，于乙醇中回流1h，生成式(IV)化合物。在碱性条件下，式(IV)化合物分别与苯甲醛类化合物Ar2CHO(VI)在室温下发生缩合反应，生成噻吩并[2,3-d]嘧啶-2-基作为A环的查耳酮类似物(化合物4a-p)。
试剂与反应条件：(a)单质硫，三乙胺，乙醇，50-55℃反应4小时；(b)丙酮酰氯，四氢呋喃，室温反应过夜；(c)i.4％氢氧化钠溶液，乙醇，回流反应2小时；ii.1mol/L盐酸；(d)i.Ar2CHO(VI)，30％氢氧化钾溶液或哌啶，甲醇，室温反应过夜；ii.1mol/L盐酸。
在本发明提供的如通式(I)所示含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物的制备方法中，其中，中间体(V)可以通过如下路线合成：
将式(IX)化合物(当R1为甲基，R2为氢时为丙醛)、氰乙酸乙酯、沉降硫、三乙胺和N,N-二甲基甲酰胺的混合物，室温反应4h，生成式(XII)化合物。将式(XII)化合物与氯乙腈溶于1,4-二氧六环，室温下通入干燥的氯化氢气体，生成式(XIII)化合物。在碘化钾存在下，式(XIII)化合物与N-甲基吗啉N-氧化物在四氢呋喃中回流反应，生成式(V)化合物。在室温条件下，式(V)化合物与苯乙酮类化合物(VII，Ar1COCH3)在碱性条件下发生缩合反应，得到噻吩并[2,3-d]嘧啶-2-基作为B环的查耳酮类似物(化合物8a-p)。
试剂与反应条件：(a)单质硫，三乙胺，N,N-二甲基甲酰胺，室温反应4小时；(b)i.氯乙腈，干燥的氯化氢气体，1,4-二氧六环，室温反应5小时；ii.25％氨水；(c)N-甲基吗啉-N-氧化物，碘化钾，干燥的四氢呋喃；(d)i.苯乙酮类化合物(VII，Ar1COCH3)，20-50％氢氧化钾溶液，甲醇，室温反应过夜；ii.1mol/L盐酸。
核磁共振氢谱(1H NMR)显示，在所合成的查耳酮类似物中，所有的C＝C双键均为单一的几何构型，而且两个双键碳上的氢的耦合常数(coupling constant)为15.6或16.2Hz，因此均为E-式构型(E-configuration)。
另一方面，本发明提供了一种包含上述噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物的药用组合物。该药用组合物包括药理学上有效量的式(I)化合物和药学上可接受的辅料。对于本领域技术人员而言，这些辅料都是已知的，例如，生理盐水，明胶，阿拉伯树胶，乳糖，微晶纤维素，淀粉，改性淀粉，纤维素，改性纤维素，羟乙酸钠，磷酸氢钙，硬脂酸镁，滑石，胶体二氧化硅等。此外，这些组合物还可进一步地包含：稳定剂，润湿剂，乳化剂，甜味剂，香味剂，缓冲剂等。
本发明提供的包含上述噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物的药用组合物，根据需要，能够配制成用于口服给药的固体或液体形式，如片剂、丸剂、口服液等；用于非肠道给药的无菌溶液、悬浮液或乳液形式，喷雾剂等。
另一方面，本发明提供了式(I)化合物在制备抗肿瘤药物中的应用。本发明的化合物可用于治疗乳腺癌、结肠癌、肺癌、宫颈癌、或肝癌等。
实验证明，本发明的式(I)的化合物具有抗肿瘤活性，不仅对人乳腺癌(MFC-7和MDA-MB-231)、人宫颈癌(HeLa)、人结肠癌(HCT-116和HT-29)和人肺癌细胞株(A549)细胞的增殖具有抑制作用，而且对人肝癌细胞株(HepG2)具有抑制作用，可用作抗肿瘤药物。
本发明的其它特征和优点将在随后的说明书中阐述，并且，部分地从说明书中变得显而易见，或者通过实施本发明而了解。本发明的目的和其他优点可通过在说明书、权利要求书中所特别指出的结构来实现和获得。
具体实施方式
为使本申请的目的、技术方案和优点更加清楚明白，下文中将对本发明的实施例进行详细说明。需要说明的是，在不冲突的情况下，本申请中的实施例及实施例中的特征可以相互任意组合。
熔点用XT5B精密显微熔点仪测定，温度未校正。高效液相色谱(HPLC)用AgilentSeries 1200(色谱柱：C18,4.5×150mm)测定，检测波长238或280nm，流动相为MeOH:H2O＝7:3，用于抗肿瘤活性实验的化合物的纯度≥95％。核磁共振氢谱和碳谱(1H NMR、13C NMR)用Varian VNMRS-600核磁共振谱仪，在600MHz或150MHz测定，TMS为内标。电子轰击质谱(MS(EI))用Shimadzu的GCMS-QP2010Plus气相色谱/质谱联用仪测定。高分辨电喷雾质谱(HRMS(ESI))用Thermo Scientific的LTQ Orbitrap质谱仪测定。柱色谱采用200-300目的硅胶填充。
苯乙酮、4-氯苯乙酮、4-氟苯乙酮、4-硝基苯乙酮、苯甲醛、4-甲氧基苯甲醛、2,4-二甲氧基苯甲醛、4-羟基-3-甲氧基苯甲醛购自天津碧橙蓝试剂公司；4-甲氧基苯乙酮、4-溴苯乙酮购自百灵威试剂公司；4-羟基-3-甲氧基苯乙酮、4-氟苯甲醛、3,4,5-三甲氧基苯甲醛、2,4,6-三甲氧基苯甲醛购自TCI试剂公司；2,4-二甲氧基苯乙酮、2,4,6-三甲氧基苯乙酮、3,4,5-三甲氧基苯乙酮、4-甲基苯乙酮购自Sigma试剂公司。其它原料均为市售化学试剂。
人肺癌细胞株A549、人结肠癌细胞株HCT-116、HT-29、人乳腺癌细胞株MCF-7、MDA-MB-231、人宫颈癌细胞株HeLa及人肝癌细胞株HepG2均由DNA损伤应答北京市重点实验室提供。DMEM培养基、胎牛血清及0.25％胰酶(Trypsin-EDTA)均购自Hyclone公司。双抗(青霉素-链霉素)购自Gemini公司。体外抗肿瘤活性实验所使用的CellTiter 
MTS细胞增殖试剂盒购自Promega公司。
缩写词：
PE＝石油醚
EtOAc＝乙酸乙酯
Ph＝苯基；
DCM＝二氯甲烷；
m.p.＝熔点；
1H NMR＝核磁共振氢谱；
13C NMR＝核磁共振碳谱；
HRMS(ESI)＝高分辨质谱(电喷雾电离)；
DMSO-d6＝氘代二甲基亚砜；
MTS＝3-(4,5-二甲基噻唑-2-基)-5-(3-(羧基甲氧基苯基)-2-(4-磺酸基苯基)-2H-四氮唑，内盐
准备例1
2-氨基-5-甲基噻吩-3-甲酰胺(式(XI)化合物，其中，R1为甲基，R2为氢)的制备
将氰乙酸乙酯(3.4g,30mmol)溶于四氢呋喃(10mL)中，加入浓氨水(15mL)，室温搅拌反应24h。反应混合物旋转蒸发除去大部分溶剂，剩余棕色溶液于冰箱中放置过夜。滤集析出的固体，用石油醚洗涤(10mL×3)，真空箱中干燥，得到氰乙酸乙酯粗品2.3g直接用于下一步反应。
将氰乙酰胺(0.84g,10mmol)、丙醛(0.58g,10mmol)、沉降硫(0.32g,10mmol)、三乙胺(1.0g,10mmol)与乙醇(30mL)的混合物，于50-55℃搅拌反应4h。旋转蒸发除去部分溶剂，剩余溶液溶于乙酸乙酯(100mL)，用饱和食盐水洗涤(100mL×3)，无水硫酸钠干燥过夜。滤除干燥剂，滤液旋转蒸发除去溶剂，残余物用硅胶柱色谱法提纯(洗脱液：PE/EtOAc＝1:1)，得淡黄色固体0.95g，收率71％,mp 119-121℃。1H NMR(600MHz,DMSO-d6)δ:2.17(d,J＝1.2Hz,3H,CH3),6.64(br s,1H,1/2CONH2),6.69(d,J＝1.2Hz,1H,thiophene 4-H),7.05(brs,3H,1/2CONH2,NH2).EI-MS m/z:156(M+).
5-甲基-2-(2-氧代丙酰基氨基)噻吩-3-甲酰胺(式(VIII)化合物，其中，R1为甲基，R2为氢)的制备
将丙酮酸(0.88g,10mmol)溶于干燥的二氯甲烷(5mL)中，室温下滴加二氯亚砜(1.3g,11mmol)。搅拌5分钟后，升温至回流，继续反应2h。将反应液冷却至室温，旋转蒸发除去溶剂。加入10mL二氯甲烷，旋转蒸发除去，重复2次，把二氯亚砜、氯化氢、二氧化硫等除尽，得到油状液体1g，收率94％，直接用于下一步反应。
将2-氨基-5-甲基噻吩-3-甲酰胺(0.78g,5mmol)和丙酮酰氯(0.64g,6mmol)溶于干燥的四氢呋喃(5mL)中，室温搅拌反应过夜。滤除析出的固体，用四氢呋喃洗涤。合并滤液和洗液，旋转蒸发除去溶剂，残余物混于冷的甲醇(30mL)中，抽滤，得淡黄色固体。粗产物用硅胶柱色谱法提纯(洗脱液：petroleum/ethyl acetate＝1:1)，得淡黄色固体0.79g，收率70％，mp 211-215℃。1H NMR(600MHz,DMSO-d6)δ:2.38(d,J＝1.2Hz,3H,CH3),2.43(s,3H,CH3CO),7.16(d,J＝1.2Hz,1H,thiophene 4-H),7.54(br s,1H,1/2CONH2),7.86(br s,1H,1/2CONH2),12.87(s,1H,NH).EI-MS m/z:226(M+).
6-甲基-2-乙酰基-噻吩并[2,3-d]嘧啶-4(3H)-酮(式(IV)化合物，其中，R1为甲基，R2为氢)的制备
将5-甲基-2-(2-氧代丙酰胺基)噻吩-3-甲酰胺(0.23g,1mmol)溶于4％氢氧化钠溶液(4mL)和乙醇(1mL)的混合液中，加热回流2h。冷却至室温，用1mol/L的盐酸调节pH 4-5，有棕色絮状固体析出。滤除析出的固体，滤液用乙酸乙酯萃取(10mL×3)，合并有机相，用饱和食盐水洗涤(15mL×3)，无水硫酸钠干燥过夜。旋转蒸发除去溶剂，残余物用硅胶柱色谱法提纯(洗脱液：DCM/MeOH＝98:2)，得淡黄色固体0.12g，收率58％，mp＞350℃。1H NMR(600MHz,DMSO-d6)δ:2.33(s,3H,CH3CO),2.46(d,J＝1.2Hz,3H,CH3),7.0(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H).EI-MS m/z:208(M+).
化合物4a-p的合成通法
将6-甲基-2-乙酰基-4-氧代噻吩并[2,3-d]嘧啶(式(V)化合物，其中，R1为甲基，R2为氢)(62mg,0.3mmol)和氢氧化钾(56mg,1mmol)配成30％的水溶液(对于化合物4k和4n-p，使用哌啶(0.1mL,1mmol)代替氢氧化钾水溶液)溶于甲醇(1mL)中，加入到反应液中，室温搅拌30min。加入不同的苯甲醛或芳杂醛(0.4mmol)，室温搅拌过夜。反应液用1mol/L盐酸调节pH 2-3，滤集析出的固体，用少量甲醇洗涤，晾干。除另有说明外，粗品用甲醇重结晶，得目标化合物4a-p。
实施例1
(E)-6-甲基-2-(3-苯基丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物4a)
收率61％，黄色固体，mp 234-237℃。1H NMR(600MHz,DMSO-d6)δ:2.55(d,J＝1.2Hz,3H,CH3),7.17(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.36(d,J＝15.6Hz,1H,COCH＝),7.61(t,J＝7.8Hz,2H,Ph 3′-H,5′-H),7.73(t,J＝7.8Hz,1H,Ph 4′-H),8.13(d,J＝7.8Hz,2H,Ph 2′-H,6′-H),8.33(d,J＝15.6Hz,1H,CH＝),12.82(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.74,119.65,124.85,128.73(2C),129.03(2C),129.85,133.89,134.78,136.64,139.42,149.52,157.34,162.88,188.53.HRMS(ESI)m/z:C16H13N2O2S([M+H]+)理论值:297.0698；实测值:297.0691.
实施例2
(E)-6-甲基-2-(3-(4-甲氧基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物4b)
收率47％，黄色固体，mp 268-271℃。1H NMR(600MHz,DMSO-d6)δ:2.54(s,3H,CH3),3.89(s,3H,OCH3),7.12(d,J＝8.4Hz,2H,Ph 3′-H,5′-H),7.16(s,1H,噻吩并[2,3-d]嘧啶5-H),7.31(d,J＝15.6Hz,1H,COCH＝),8.13(d,J＝8.4Hz,2H,Ph 2′-H,6′-H),8.32(d,J＝15.6Hz,1H,CH＝),12.75(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.74,55.71,113.89,114.34(2C),119.63,129.64,129.97,130.44,131.25(2C),134.08,139.31,149.67,157.39,163.83,186.54.HRMS(ESI)m/z:C17H15N2O3S([M+H]+)理论值:327.0803；实测值:327.0792.
实施例3
(E)-6-甲基-2-(3-(2,4-二甲氧基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物4c)
收率70％，黄色固体，mp 246-251℃。1H NMR(600MHz,DMSO-d6)δ:2.54(d,J＝1.8Hz,3H,CH3),3.88(s,3H,OCH3),3.91(s,3H,OCH3),6.68(dd,J＝9.0,2.4Hz,1H,Ph 5′-H),6.71(d,J＝2.4Hz,1H,Ph 3′-H),7.14(d,J＝1.8Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.22(d,J＝15.6Hz,1H,COCH＝),7.67(d,J＝9.0Hz,1H,Ph 6′-H),8.03(d,J＝15.6Hz,1H,CH＝),12.71(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.72,55.60,56.50,113.95,114.08,119.57,119.78,124.67,128.03,133.15,134.19,139.07,149.56,152.46,153.07,157.31,162.99,190.74.HRMS(ESI)m/z:C18H17N2O4S([M+H]+)理论值:357.0909；实测值:357.0894.
实施例4
(E)-6-甲基-2-(3-(2,4,6-三甲氧基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物4d)
收率56％，黄色固体，mp 233-236℃(DMF重结晶)。1H NMR(600MHz,CDCl3)δ:2.52(d,J＝1.2Hz,3H,CH3),3.74(s,6H,2OCH3),3.85(s,3H,OCH3),6.33(s,2H,Ph 3′-H,5′-H),7.0(d,J＝15.6Hz,1H,COCH＝),7.12(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.38(d,J＝15.6Hz,1H,CH＝),12.61(s,1H,NH).13C NMR(150MHz,CDCl3)δ:15.69,55.56,55.93(2C),91.10(2C),110.20,119.55,124.61,133.96,135.82,139.08,149.52,157.23,158.48(2C),162.63,162.89,192.04.HRMS(ESI)m/z:C19H19N2O5S([M+H]+)理论值:387.1015；实测值:387.1005.
实施例5
(E)-6-甲基-2-(3-(3,4,5-三甲氧基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物4e)
收率60％，黄色固体，mp＞330℃(DMF重结晶)。1H NMR(600MHz,DMSO-d6)δ:2.55(s,3H,CH3),3.79(s,3H,OCH3),3.91(s,6H,2OCH3),7.18(s,1H,噻吩并[2,3-d]嘧啶5-H),7.35(d,J＝15.6Hz,1H,COCH＝),7.42(s,2H,Ph2′-H,6′-H),8.30(d,J＝15.6Hz,1H,CH＝),12.73(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:16.14,56.01,56.38(2C),91.54(2C),110.65,120.0,125.06,134.41,136.26,139.53,149.97,157.68,158.93(2C),163.08,163.34,192.49.HRMS(ESI)m/z:C19H19N2O5S([M+H]+)理论值:387.1015；实测值:387.1006.
实施例6
(E)-6-甲基-2-(3-(4-羟基-3-甲氧基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物4f)
收率69％，黄色固体，mp＞330℃。1H NMR(600MHz,DMSO-d6)δ:2.54(d,J＝1.2Hz,3H,CH3),3.88(s,3H,OCH3),6.95(d,J＝8.4Hz,1H,Ph 5′-H),7.15(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.29(d,J＝15.6Hz,1H,COCH＝),7.59(d,J＝2.4Hz,1H,Ph 2′-H),7.76(dd,J＝8.4,2.4Hz,1H,Ph 6′-H),8.30(d,J＝15.6Hz,1H,CH＝),10.28(s,1H,OH),12.72(br s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:16.15,56.14,111.94,115.57,120.03,124.82,125.12,129.09,130.38,134.14,139.60,148.45,150.16,153.19,157.82,163.41,186.53.HRMS(ESI)m/z:C17H15N2O4S([M+H]+)理论值:343.0753；实测值:343.0744.
实施例7
(E)-6-甲基-2-(3-(4-甲基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物4g)
收率64％，黄色固体，mp 264-267℃。1H NMR(600MHz,DMSO-d6)δ:2.42(s,3H,CH3),2.55(d,J＝1.2Hz,3H,CH3),7.17(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.33(d,J＝15.6Hz,1H,COCH＝),7.42(d,J＝8.4Hz,2H,Ph3′-H,5′-H),8.05(d,J＝8.4Hz,2H,Ph 2′-H,6′-H),8.32(d,J＝15.6Hz,1H,CH＝),12.77(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.74,21.26,119.63,124.80,128.88(2C),129.61(2C),129.87,134.19,134.49,139.38,144.56,149.57,157.36,162.92,187.85.HRMS(ESI)m/z:C17H15N2O2S([M+H]+)理论值:311.0854；实测值:311.0841.
实施例8
(E)-6-甲基-2-(3-(4-溴苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物4h)
收率61％，黄色固体，mp＞330℃。1H NMR(600MHz,DMSO-d6)δ:2.59(d,J＝1.2Hz,3H,CH3),7.26(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.68(d,J＝8.4Hz,2H,Ph 2′-H,6′-H),7.83(d,J＝8.4Hz,2H,Ph 3′-H,5′-H),7.86(d,J＝16.2Hz,1H,COCH＝),8.03(d,J＝16.2Hz,1H,CH＝),12.54(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.92,120.15,120.20,124.78,127.41,130.98(2C),132.09(2C),133.39,142.18,144.18,147.66,156.70,160.77,181.95.HRMS(ESI)m/z:C16H12BrN2O2S([M+H]+)理论值:374.9803,376.9782；实测值:374.9795,376.9765.
实施例9
(E)-6-甲基-2-(3-(4-氯苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物4i)
收率57％，黄色固体，mp 220-223℃。1H NMR(600MHz,DMSO-d6)δ:2.55(d,J＝1.2Hz,3H,CH3),7.17(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.35(d,J＝15.6Hz,1H,COCH＝),7.68(d,J＝9.0Hz,2H,Ph 2′-H,6′-H),8.15(d,J＝9.0Hz,2H,Ph 3′-H,5′-H),8.30(d,J＝15.6Hz,1H,CH＝),12.78(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.92,120.14,120.17,124.77,127.40,130.96(2C),132.07(2C),133.38,142.16,144.16,147.64,156.69,160.75,181.93.HRMS(ESI)m/z:C16H12ClN2O2S([M+H]+)理论值:331.0308,333.0279；实测值:331.0302,333.0268.
实施例10
(E)-6-甲基-2-(3-(4-氟苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物4j)
收率45％，黄色固体，mp 217-219℃。1H NMR(600MHz,DMSO-d6)δ:2.55(s,3H,CH3),7.17(s,1H,噻吩并[2,3-d]嘧啶5-H),7.34(d,J＝15.6Hz,1H,COCH＝),7.44(t,J＝8.4Hz,2H,Ph 3′-H,5′-H),8.23(dd,J＝8.4,6.0Hz,2H,Ph2′-H,6′-H),8.31(d,J＝15.6Hz,1H,CH＝),12.77(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.92,115.96(d,J＝21.6Hz,2C),119.87,123.86(d,J＝1.8Hz),125.12,130.70(d,J＝8.55Hz,2C),131.65,132.71,140.56,158.45,163.14(d,J＝247.05Hz),164.67,168.27,189.66.HRMS(ESI)m/z:C16H12FN2O2S([M+H]+)理论值:315.0604；实测值:315.0593.
实施例11
(E)-6-甲基-2-(3-(4-硝基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物4k)
收率56％，黄色固体，mp 284-286℃。1H NMR(600MHz,CF3COOD)δ:2.60(s,3H,CH3),7.30(s,1H,噻吩并[2,3-d]嘧啶5-H),7.89(d,J＝15.6Hz,1H,COCH＝),8.31(d,J＝15.6Hz,1H,CH＝),8.70(d,J＝4.8Hz,2H,Ph 2′-H,6′-H),9.03(d,J＝4.8Hz,2H,Ph 3′-H,5′-H).13CNMR(150MHz,CF3COOD)δ:16.21,119.52,121.46,124.36(2C),126.23,129.97(2C),140.23,144.38,145.95,147.52,148.97,161.36(overlapped with CF3COOH),164.38,182.15.HRMS(ESI)m/z:C16H12N3O4S([M+H]+)理论值:342.0549；实测值:342.0538.
实施例12
(E)-6-甲基-2-(3-(呋喃-2-基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物4l)
收率80％，黄色固体，mp 294-296℃。1H NMR(600MHz,DMSO-d6)δ:2.55(d,J＝1.2Hz,3H,CH3),6.84(dd,J＝3.6,1.2Hz,1H,furan 4′-H),7.16(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.38(d,J＝15.6Hz,1H,COCH＝),7.83(d,J＝3.6Hz,1H,furan 3′-H),8.08(d,J＝15.6Hz,1H,CH＝),8.15(d,J＝1.2Hz,1H,furan 5′-H),12.74(s,1H,NH).13CNMR(150MHz,DMSO-d6)δ:15.91,113.52,116.21,119.05,120.12,127.27,131.41,142.03,147.21,147.72,150.97,156.68,160.85,181.41.HRMS(ESI)m/z:C14H11N2O3S([M+H]+)理论值:287.0490；实测值:287.0482.
实施例13
(E)-6-甲基-2-(3-(噻吩-2-基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物4m)
收率61％，黄色固体，mp 308-311℃。1H NMR(600MHz,DMSO-d6)δ:2.59(d,J＝1.2Hz,3H,CH3),7.24(dd,J＝4.8,3.6Hz,1H,thiophene 4′-H),7.25(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.68(d,J＝15.6Hz,1H,COCH＝),7.75(d,J＝3.6Hz,1H,thiophene3′-H),7.88(d,J＝4.8Hz,1H,thiophene 5′-H),8.07(d,J＝15.6Hz,1H,CH＝),12.49(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.92,117.66,120.13,127.32,129.14,131.68,134.62,138.32,139.55,142.03,147.72,156.69,160.82,181.36.HRMS(ESI)m/z:C14H11N2O2S2([M+H]+)理论值:303.0262；实测值:303.0251.
实施例14
(E)-6-甲基-2-(3-(吡啶-2-基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物4n)
收率56％，黄色固体，mp＞330℃。1H NMR(600MHz,DMSO-d6)δ:2.60(d,J＝1.2Hz,3H,CH3),7.27(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.48(ddd,J＝7.8,4.8,1.2Hz,1H,吡啶4′-H),7.85(d,J＝7.8Hz,1H,吡啶6′-H),7.87(d,J＝15.6Hz,1H,COCH＝),7.92(td,J＝7.8,1.8Hz,1H,吡啶5′-H),8.41(d,J＝15.6Hz,1H,CH＝),8.73(d,J＝4.8Hz,1H,吡啶3′-H),12.57(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.94,120.20,122.80,125.38,126.29,127.45,137.42,142.33,143.86,147.67,150.27,152.08,156.73,160.80,182.31.HRMS(ESI)m/z:C15H12N3O2S([M+H]+)理论值:298.0650；实测值:298.0641.
实施例15
(E)-6-甲基-2-(3-(吡啶-3-基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物4o)
收率76％，黄色固体，mp 221-224℃。1H NMR(600MHz,DMSO-d6)δ:2.59(s,3H,CH3),7.27(s,1H,噻吩并[2,3-d]嘧啶5-H),7.51(dd,J＝7.8,4.8Hz,1H,吡啶5′-H),7.92(d,J＝16.2Hz,1H,COCH＝),8.13(d,J＝16.2Hz,1H,CH＝),8.36(d,J＝7.8Hz,1H,吡啶4′-H),8.65(d,J＝4.8Hz,1H,吡啶6′-H),9.0(s,1H,吡啶2′-H),12.58(s,1H,NH).13C NMR(150MHz,CF3COOD)δ:16.26,120.98,126.05,128.15,128.76,130.09,134.80,138.84,143.17,143.61,145.53,147.94,157.54,161.63,182.67.HRMS(ESI)m/z:C15H12N3O2S([M+H]+)理论值:298.0650；实测值:298.0642.
实施例16
(E)-6-甲基-2-(3-(吡啶-4-基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物4p)
收率80％，黄色固体，mp 221-224℃。1H NMR(600MHz,DMSO-d6)δ:2.60(d,J＝1.2Hz,3H,CH3),7.27(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.81(d,J＝6.0Hz,2H,吡啶2′-H,6′-H),7.83(d,J＝16.2Hz,1H,COCH＝),8.19(d,J＝16.2Hz,1H,CH＝),8.70(d,J＝6.0Hz,2H,吡啶3′-H,5′-H),12.63(s,1H).13C NMR(150MHz,CF3COOD)δ:16.06,120.56,126.16(2C),128.14,129.53,139.01,142.69(2C),143.17,147.48,151.01,156.94,160.86,182.10.HRMS(ESI)m/z:C15H12N3O2S([M+H]+)理论值:298.0650；实测值:298.0642.
准备例2
2-氨基-5-甲基噻吩-3-甲酸乙酯(式(XII)化合物，其中，R1为甲基，R2为氢)的制备
将氰乙酸乙酯(5.6g,50mmol)、沉降硫(1.6g,50mmol)及三乙胺(5.0g,50mmol)与N,N-二甲基甲酰胺(20mL)混合，加热至50-55℃，搅拌30min。保持温度，向混合物中滴加丙醛(2.9g,50mmol)。滴加完毕，室温搅拌3h。将反应液倾入蒸馏水(200mL)中，混匀，用乙酸乙酯萃取(100mL×3)。合并有机相，无水硫酸钠干燥过夜。旋转蒸发除去溶剂，残余物用硅胶柱色谱法提纯(洗脱液：PE/EtOAc＝4:1)，得淡黄色固体6.0g，收率65％,m.p.46-49℃(文献值:45-47℃)。
6-甲基-2-氯甲基噻吩并[2,3-d]嘧啶-4(3H)-酮(式(XIII)化合物，其中，R1为甲基，R2为氢)的制备
将2-氨基-5-甲基噻吩-3-甲酸乙酯(14.0g,75mmol)和氯乙腈(6.8g,90mmol)溶于1,4-二氧六环(50mL)中，室温搅拌下，持续通入干燥的氯化氢气体5h。旋转蒸发除去溶剂，残余物用浓盐酸调节pH 3-4，室温搅拌1h后有大量固体析出。滤集析出的固体，用少量二氯甲烷洗涤，晾干。粗品用1,4-二氧六环重结晶，得到类白色固体11.0g，收率69％,m.p.211-214℃.1H NMR(600MHz,DMSO-d6)δ:2.51(d,J＝1.2Hz,3H,CH3),4.56(s,2H,CH2Cl),7.11(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),12.73(s,1H,NH).EI-MS m/z:214,216(M+)。
6-甲基-4-氧代噻吩并[2,3-d]嘧啶-2-甲醛(式(V)化合物，其中，R1为甲基，R2为氢)的制备
将6-甲基-2-氯甲基-4-氧代噻吩并[2,3-d]嘧啶(1.1g,5mmol)、N-甲基吗啉N-氧化物(1.2g,10mmol)和碘化钾(1.1g,6.5mmol)与干燥的四氢呋喃(10mL)混合，加热回流2h。冷却至室温，滤除不溶物，固体用10mL四氢呋喃洗涤。滤液旋转蒸发除去溶剂，残余物用硅胶柱色谱法提纯(洗脱液:DCM/MeOH＝98:2)，得类白色固体0.56g，收率58％,m.p.190-192℃.1H NMR(600MHz,DMSO-d6)δ:2.57(d,J＝1.2Hz,3H,CH3),7.24(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),9.50(s,1H,CHO),12.80(s,1H,NH).EI-MS m/z:194(M+)。
化合物8a-p的合成通法
将不同的苯乙酮、杂环乙酮(0.55mmol)溶于甲醇(2mL)中，将氢氧化钾(84mg,1.5mmol)配成15％(8k,8n-p)、30％(8a-e,8g-j)或50％(8f,8l,8m)的水溶液，加入到反应液中，室温搅拌30min。加入6-甲基-4-氧代噻吩并[2,3-d]嘧啶-2-甲醛(97mg,0.5mmol)，室温反应过夜。反应液用1mol/L盐酸调pH 2-3，滤集析出的固体，用少量甲醇洗涤，晾干。除另有说明外，粗品用甲醇重结晶，得目标化合物8a-p。
实施例17
(E)-6-甲基-2-(3-氧代-3-苯基丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物8a)
收率47％，黄色固体，mp 200-205℃。1H NMR(600MHz,DMSO-d6)δ:2.55(d,J＝1.2Hz,3H,CH3),7.17(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.36(d,J＝15.6Hz,1H,COCH＝),7.62(t,J＝7.8Hz,2H,Ph 3′-H,5′-H),7.73(t,J＝7.8Hz,1H,Ph 4′-H),8.14(d,J＝7.8Hz,2H,Ph 2′-H,6′-H),8.33(d,J＝15.6Hz,1H,CH＝),12.81(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.74,119.65,124.85,128.73(2C),129.03(2C),129.85,133.89,134.78,136.64,139.42,149.52,157.34,162.88,188.54.HRMS(ESI)m/z:C16H13N2O2S([M+H]+)理论值:297.0698；实测值:297.0688.
实施例18
(E)-6-甲基-2-(3-氧代-3-(4-甲氧基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物8b)
收率46％，黄色固体，mp 245-248℃。1H NMR(600MHz,DMSO-d6)δ:2.55(d,J＝0.6Hz,3H,CH3),3.89(s,3H,OCH3),7.13(d,J＝9.0Hz,2H,Ph 3′-H,5′-H),7.16(d,J＝0.6Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.31(d,J＝15.6Hz,1H,COCH＝),8.14(d,J＝9.0Hz,2H,Ph 2′-H,6′-H),8.33(d,J＝15.6Hz,1H,CH＝),12.75(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.73,55.69,114.32(2C),119.61,124.74,129.63,129.95,131.23(2C),134.06,139.28,149.66,157.37,162.94,163.82,186.52.HRMS(ESI)m/z:C17H15N2O3S([M+H]+)理论值:327.0803；实测值:327.0794.
实施例19
(E)-6-甲基-2-(3-氧代-3-(2,4-二甲氧基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物8c)
收率51％，黄色固体，mp 220-223℃。1H NMR(600MHz,DMSO-d6)δ:2.54(s,3H,CH3),3.87(s,3H,OCH3),3.91(s,3H,OCH3),6.67(d,J＝9.0Hz,1H,Ph 5′-H),6.71(s,1H,Ph 3′-H),7.14(s,1H,噻吩并[2,3-d]嘧啶5-H),7.22(d,J＝15.6Hz,1H,COCH＝),7.67(d,J＝9.0Hz,1H,Ph 6′-H),8.03(d,J＝15.6Hz,1H,CH＝),12.71(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.71,55.73,56.17,98.64,106.42,119.53,120.40,124.52,131.90,132.42,134.86,138.81,149.84,157.38,160.81,163.12,164.75,188.16.HRMS(ESI)m/z:C18H17N2O4S([M+H]+)理论值:357.0909；实测值:357.0899.
实施例20
(E)-6-甲基-2-(3-氧代-3-(2,4,6-三甲氧基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物8d)
收率35％，黄色固体，mp 233-237℃(DMF重结晶)。1H NMR(600MHz,DMSO-d6)δ:2.52(d,J＝1.2Hz,3H,CH3),3.74(s,6H,2OCH3),3.85(s,3H,OCH3),6.33(s,2H,Ph 3′-H,5′-H),7.0(d,J＝16.2Hz,1H,COCH＝),7.13(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.38(d,J＝16.2Hz,1H,CH＝),12.61(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.69,55.56,55.93(2C),91.10(2C),110.20,119.55,124.61,133.96,135.82,139.08,149.52,157.23,158.48(2C),162.63,162.89,192.04.HRMS(ESI)m/z:C19H19N2O5S([M+H]+)理论值:387.1015；实测值:387.1005.
实施例21
(E)-6-甲基-2-(3-氧代-3-(3,4,5-三甲氧基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物8e)
收率52％，黄色固体，mp 211-213℃(DMF重结晶)。1H NMR(600MHz,DMSO-d6)δ:2.55(d,J＝1.2Hz,3H,CH3),3.79(s,3H,OCH3),3.91(s,6H,2OCH3),7.18(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.34(d,J＝15.6Hz,1H,COCH＝),7.42(s,2H,Ph 2′-H,6′-H),8.30(d,J＝15.6Hz,1H,CH＝),12.73(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.74,56.28(2C),60.25,106.50(2C),119.64,124.82,129.75,131.96,134.86,139.46,142.67,149.53,153.01(2C),157.36,162.89,187.31.HRMS(ESI)m/z:C19H19N2O5S([M+H]+)理论值:387.1015；实测值:387.1005.
实施例22
(E)-6-甲基-2-(3-氧代-3-(4-羟基-3-甲氧基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物8f)
收率47％，黄色固体，mp 256-260℃。1H NMR(600MHz,DMSO-d6)δ:2.54(d,J＝1.2Hz,3H,CH3),3.88(s,3H,OCH3),6.95(d,J＝8.4Hz,1H,Ph5′-H),7.15(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.29(d,J＝15.6Hz,1H,COCH＝),7.58(d,J＝1.8Hz,1H,Ph 2′-H),7.76(dd,J＝8.4,1.8Hz,1H,Ph 6′-H),8.30(d,J＝15.6Hz,1H,CH＝),10.27(s,1H,OH),12.72(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.71,55.70,111.50,115.13,119.59,124.38,124.68,128.65,129.95,133.69,139.15,148.01,149.72,152.75,157.37,162.97,186.09.HRMS(ESI)m/z:C17H15N2O4S([M+H]+)理论值:343.0753；实测值:343.0745.
实施例23
(E)-6-甲基-2-(3-氧代-3-(4-甲基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物8g)
收率60％，黄色固体，mp 248-249℃。1H NMR(600MHz,DMSO-d6)δ:2.42(s,3H,CH3),2.55(d,J＝1.2Hz,3H,CH3),7.17(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.33(d,J＝15.6Hz,1H,COCH＝),7.42(d,J＝8.4Hz,2H,Ph3′-H,5′-H),8.04(d,J＝8.4Hz,2H,Ph 2′-H,6′-H),8.32(d,J＝15.6Hz,1H,CH＝),12.77(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.75,21.27,119.64,124.81,128.89(2C),129.61(2C),129.87,134.20,134.49,139.39,144.57,149.58,157.36,162.92,187.85.HRMS(ESI)m/z:C17H15N2O2S([M+H]+)理论值:311.0854；实测值:311.0845.
实施例24
(E)-6-甲基-2-(3-氧代-3-(4-溴苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物8h)
收率68％，黄色固体，mp 230-234℃。1H NMR(600MHz,DMSO-d6)δ:2.55(s,3H,CH3),7.17(s,1H,噻吩并[2,3-d]嘧啶5-H),7.35(d,J＝15.6Hz,1H,COCH＝),7.83(d,J＝8.4Hz,2H,ph 3′-H,5′-H),8.06(d,J＝8.4Hz,2H,Ph 2′-H,6′-H),8.28(d,J＝15.6Hz,1H,CH＝),12.78(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.75,119.66,124.90,128.15,129.45,130.70(2C),132.11(2C),135.09,135.63,139.55,149.41,157.32,162.86,187.67.HRMS(ESI)m/z:C16H12BrN2O2S([M+H]+)理论值:374.9803,376.9782；实测值:374.9797,376.9770.
实施25
(E)-6-甲基-2-(3-氧代-3-(4-氯苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物8i)
收率39％，黄色固体，mp 236-240℃。1H NMR(600MHz,CF3COOD)δ:2.55(s 3H,CH3),7.17(s,1H,噻吩并[2,3-d]嘧啶5-H),7.35(d,J＝15.6Hz,1H,COCH＝),7.68(d,J＝9.0Hz,2H,Ph 3′-H,5′-H),8.15(d,J＝9.0Hz,2H,Ph 2′-H,6′-H),8.30(d,J＝15.6Hz,1H,CH＝),12.78(s,1H,NH).13C NMR(150MHz,CF3COOD)δ:13.88,119.21,125.03,128.78,129.46(2C),130.60(2C),133.15,134.59,143.61,146.53,149.35,158.32,162.10(与CF3COOH重叠),189.35.HRMS(ESI)m/z:C16H12ClN2O2S([M+H]+)理论值:331.0308,333.0279；实测值:331.0301,333.0268.
实施例26
(E)-6-甲基-2-(3-氧代-3-(4-氟苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物8j)
收率57％，黄色固体，mp 243-246℃。1H NMR(600MHz,CF3COOD)δ:2.55(d,J＝1.2Hz,3H,CH3),7.17(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.34(d,J＝15.6Hz,1H,COCH＝),7.44(t,J＝9.0Hz,2H,Ph 3′-H,5′-H),8.23(dd,J＝9.0,5.4Hz,2H,Ph 2′-H,6′-H),8.31(d,J＝15.6Hz,1H,CH＝),12.77(s,1H,NH).13C NMR(150MHz,CF3COOD)δ:13.86,116.35(d,J＝22.65Hz,2C),119.24,125.07,128.31(d,J＝3.75Hz),131.30,132.54(d,J＝10.35Hz,2C),135.01,146.55,149.46,158.17,162.08(与CF3COOH重叠),167.98(d,J＝259.8Hz),188.84.HRMS(ESI)m/z:C16H12FN2O2S([M+H]+)理论值:315.0604；实测值:315.0594.
实施例27
(E)-6-甲基-2-(3-氧代-3-(4-硝基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物8k)
收率41％，黄色固体，mp 236-238℃。1H NMR(600MHz,DMSO-d6)δ:2.55(d,J＝1.2Hz,3H,CH3),7.18(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.35(d,J＝15.6Hz,1H,COCH＝),7.68(d,J＝8.4Hz,2H,Ph 2′-H,6′-H),8.15(d,J＝8.4Hz,2H,Ph 3′-H,5′-H),8.30(d,J＝15.6Hz,1H,CH＝),12.78(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.50,119.0,123.51,123.83(2C),124.03,129.51(2C),130.11,136.91,141.29,149.94,157.49,158.02,162.90,196.91.HRMS(ESI)m/z:C16H12N3O4S([M+H]+)理论值:342.0549；实测值:342.0540.
实施例28
(E)-6-甲基-2-(3-氧代-3-(呋喃-2-基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物8l)
收率60％，黄色固体，mp 255-259℃(柱色谱提纯，洗脱液：DCM/MeOH＝98:2)。1HNMR(600MHz,DMSO-d6)δ:2.55(d,J＝1.2Hz,3H,CH3),6.84(dd,J＝3.6,1.8Hz,1H,furan 4′-H),7.17(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.39(d,J＝15.6Hz,1H,COCH＝),7.83(d,J＝3.6Hz,1H,furan 3′-H),8.08(d,J＝15.6Hz,1H,CH＝),8.15(d,J＝1.8Hz,1H,furan5′-H),12.74(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.73,113.20,119.61,120.97,124.82,129.75,133.73,139.37,149.39,152.43,157.30,162.27,162.89,175.47.HRMS(ESI)m/z:C14H11N2O3S([M+H]+)理论值:287.0490；实测值:287.0481.
实施例29
(E)-6-甲基-2-(3-氧代-3-(噻吩-2-基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物8m)
收率66％，黄色固体，mp 201-204℃(DMF/H2O＝3:1重结晶)。1H NMR(600MHz,DMSO-d6)δ:2.55(d,J＝1.2Hz,3H,CH3),7.17(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.35(dd,J＝4.8,4.2Hz,1H,thiophene 4′-H),7.35(d,J＝15.6Hz,1H,COCH＝),8.16(dd,J＝4.8,1.2Hz,1H,thiophene 3′-H),8.22(d,J＝15.6Hz,1H,CH＝),8.28(dd,J＝4.2,1.2Hz,1H,thiophene 5′-H),12.74(s,1H,NH).13C NMR(150MHz,DMSO-d6)δ:15.75,119.64,124.86,129.26,129.71,134.09,134.82,136.96,139.47,144.47,149.36,157.33,162.88,180.70.HRMS(ESI)m/z:C14H11N2O2S2([M+H]+)理论值:303.0262；实测值:303.0253.
实施例30
(E)-6-甲基-2-(3-氧代-3-(吡啶-2-基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物8n)
收率67％，黄色固体，mp 206-209℃。1H NMR(600MHz,DMSO-d6/CF3COOD＝2:1)δ:2.55(s,3H,CH3),7.16(s,1H,噻吩并[2,3-d]嘧啶5-H),7.52(d,J＝15.6Hz,1H,COCH＝),7.75(t,J＝4.8Hz,1H,吡啶5′-H),8.09(t,J＝7.2Hz,1H,吡啶4′-H),8.13(d,J＝7.2Hz,1H,吡啶3′-H),8.75(d,J＝15.6Hz,1H,CH＝),8.84(d,J＝3.0Hz,1H,吡啶6′-H),12.84(br s,1H,NH).13C NMR(150MHz,DMSO-d6/CF3COOD)δ:16.07,113.78,116.75,119.22,120.53,127.86,131.92,142.50,147.43,148.04,151.58,157.12,158.31(与CF3COOH重叠),161.51,181.95.HRMS(ESI)m/z:C15H12N3O2S([M+H]+)理论值:298.0650；实测值:298.0642.
实施例31
(E)-6-甲基-2-(3-氧代-3-(吡啶-3-基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物8o)
收率59％，黄色固体，mp 239-241℃。1H NMR(600MHz,CF3COOD)δ:2.55(d,J＝1.2Hz,3H,CH3),7.17(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.37(d,J＝15.6Hz,1H,COCH＝),7.64(ddd,J＝7.8,4.8,0.6Hz,1H,吡啶5′-H),8.30(d,J＝15.6Hz,1H,CH＝),8.45(dt,J＝7.8,1.8Hz,1H,吡啶4′-H),8.86(dd,J＝4.8,1.8Hz,1H,吡啶6′-H),9.28(d,J＝1.8Hz,1H,吡啶2′-H),12.78(br s,1H,NH).13C NMR(150MHz,CF3COOD)δ:14.26,118.87,124.91,127.66,127.82,135.46,136.75,141.89,142.28,144.60,145.23,148.21,158.78,163.93,184.47.HRMS(ESI)m/z:C15H12N3O2S([M+H]+)理论值:298.0650；实测值:298.0641.
实施例32
(E)-6-甲基-2-(3-氧代-3-(吡啶-4-基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮(化合物8p)
收率66％，黄色固体，mp 238-239℃。1H NMR(600MHz,DMSO-d6/CF3COOD＝2:1)δ:2.55(s,3H,CH3),7.17(d,J＝1.2Hz,1H,噻吩并[2,3-d]嘧啶5-H),7.38(d,J＝15.6Hz,1H,COCH＝),7.96(dd,J＝4.8,1.8Hz,2H,吡啶3′-H,5′-H),8.22(d,J＝15.6Hz,1H,CH＝),8.88(dd,J＝4.8,1.8Hz,2H,吡啶2′-H,6′-H),12.79(s,1H,NH).13C NMR(150MHz,DMSO-d6/CF3COOD)δ:15.95,120.21,125.61(2C),125.86,129.07(2C),137.67,140.60,144.94,149.41,149.66,157.79,163.39,187.38.HRMS(ESI)m/z:C15H12N3O2S([M+H]+)理论值:298.0650；实测值:298.0642.
试验例
所有肿瘤细胞均在37℃ 5％CO2细胞培养箱中培养。待细胞铺满培养皿底部约80-90％后，吸除原培养基，沿培养皿侧边缓慢加入约5mL的1×PBS缓冲液润洗细胞。吸除PBS，加入1mL 0.25％胰蛋白酶，轻摇培养皿使其铺满整个皿底并与细胞充分接触，吸除胰蛋白酶。将培养皿置于培养箱中，消化2-3min。加入合适体积的新培养基终止细胞消化，轻轻吹打细胞，使细胞在培养基中单个悬浮分散。吸取1mL细胞悬液传至新的培养皿中，补齐培养皿中培养基到10mL。轻摇培养皿使细胞分散均匀，放入培养箱中培养。
细胞增殖抑制实验
参照文献(Cao,S.L.；Han,Y.；Yuan,C.Z.；Wang,Y.；Xiahou,Z.K.；Liao,J.；Gao,R.T.；Mao,B.B.；Zhao,B.L.；Li,Z.F.；Xu,X.Synthesis and antiproliferative activityof 4-substituted-piperazine-1-carbodithioate derivatives of2,4-diaminoquinazoline.Eur.J.Med.Chem.2013,64,401-409)的方法，使用CellTiter 
AQueous OneSolution Cell Proliferation Assay试剂盒(Promega)。待测化合物事先配成104μM的DMSO溶液，-20℃保存，解冻后使用，用培养基稀释至所需浓度。实验数据均为三次独立平行实验计算所得。
按上述细胞传代方法制得细胞悬液，5×103/well的密度接种于96孔培养板中，留出两个孔作为空白，其余每孔加入90μL细胞悬液。在培养箱中培养24h后，吸除旧培养基，空白及本底孔加入100μL新培养基，其余孔加入配好的待测化合物的培养基溶液，放入培养箱中继续培养72h。预先将冷冻保存的MTS溶液在室温下解冻，向96孔培养板每孔加入20μLMTS溶液，放入培养箱2h，使用酶标仪(Molecular Devices SpectraMax M5)检测492nm波长处各孔的光密度(optical density，OD)。按如下公式计算细胞增殖抑制率：
细胞增殖抑制率(％)＝[1-(OD试验组-OD本底组)/(OD空白组-OD本底组)]×100％
其中OD试验组、OD空白组、OD本底组分别代表在492nm波长下试验组、空白组以及本底组的光密度。通过SPSS 20for Windows软件绘制抑制率的S型曲线，计算化合物的半抑制浓度(IC50)。
表1.化合物4a-p对A549和HCT-116细胞的IC50值
如表1所示，噻吩并[2,3-d]嘧啶作为A环时的，8个化合物(4b-c、4e、4g-j和4l)对A549细胞有细胞毒活性(IC50<20μM)，其中化合物4h、4j和4l活性较好(IC50<10μM)。10个化合物(4a、4e、4g-j、4l-m和4o-p)对HCT-116细胞有细胞毒活性(IC50<20μM)，其中化合物4b、4g、4h和4l活性较好(IC50<10μM)。化合物4h和4l同时对A549和HCT-116细胞均有较好的活性，其IC50值分别为8.93、8.66μM和9.40、7.87μM。
表2.化合物8a-p对A549和HCT-116细胞的IC50值
如表2所示，噻吩并[2,3-d]嘧啶为B环时，9个化合物对A549细胞具有细胞毒活性，其中5个化合物活性较好；12个化合物对HCT-116细胞具有细胞毒活性，其中5个化合物活性较好。在苯环上连有卤素原子或4-硝基，或用杂环代替A环时，所得化合物的活性与母体化合物8a相近或降低，只有含噻吩环化合物8m活性好于8a。在苯环引入给电子基团时，除化合物8c外，其余化合物对A549和HCT-116细胞系的活性都提高了。4个化合物(8d-g)对两种细胞的的活性最好，其中化合物8d-f对HCT-116细胞的IC50值均小于5.00μM，与阳性对照5-FU活性相近。总的来说，当噻吩并[2,3-d]嘧啶作为B环时，大部分化合物的抗增殖活性要优于作为A环时化合物的活性。只有B环为4-溴、4-氟取代的苯环，或为呋喃-2-基时，所得化合物4h、4j和4l的抗增殖活性，比相应取代的化合物8h、8j和8l要好。相比于A549细胞，两系列化合物对HCT-116细胞的抗增殖活性普遍要更高一些。
表3化合物8d-f对MCF-7、MDA-MB-231、HeLa、HT-29以及MCF-10A细胞的IC50值.
进一步测试了化合物8d-f，对人乳腺癌MCF-7,MDA-MB-231、人宫颈癌HeLa人结肠癌HT-29、人肝癌HepG2细胞，以及人乳腺上皮细胞MCF-10A的细胞毒活性(表3)。化合物8d-f对测试的所有癌细胞系均有活性。但是，它们对正常细胞MCF-10A也有细胞毒性。与A549和HCT-116细胞类似，化合物8d对MCF-7、MD-MBA-231、HeLa、HT-29和HepG2细胞的IC50值也相对较低。
表4化合物4a-p、8a-p和化合物VIIa-s、VIIIa-s活性对比
Han等曾合成了以喹唑啉分别作为A、B环的查耳酮类似物VIIa-s和VIIIa-s。如表4所示，含有4-甲氧基、4-甲基、4-溴、4-氯、4-氟或呋喃-2-基的化合物4b、4g、4h、4i、4j、4l，其对HCT-116细胞的活性要优于含相同取代基的化合物VIId、VIIi、VIIj、VIIk、VIIl、VIIo。含有2,4,6-三甲氧基、3,4,5-三甲氧基或4-羟基-3-甲氧基的化合物8d-f，其对MCF-7和HCT-116细胞的活性均优于含相同取代基的化合物VIIIg、VIIIh、VIIIk。此外，8d-f还对HepG2细胞表现出较好的细胞毒活性，而化合物VIIa-s和VIIIa-s则均未能对HepG2细胞表现出任何活性。
综上所述，以上仅为本发明的较佳实施例而已，并非用于限定本发明的保护范围，因此，凡在本发明的精神和原则之内所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内
虽然本申请所揭露的实施方式如上，但所述的内容仅为便于理解本申请而采用的实施方式，并非用以限定本申请。任何本申请所属领域内的技术人员，在不脱离本申请所揭露的精神和范围的前提下，可以在实施的形式及细节上进行任何的修改与变化，但本申请的专利保护范围，仍须以所附的权利要求书所界定的范围为准。
Claims (9)
1.含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物，如通式(I)所示：
其中，式(I)中Ar1和Ar2中的一个为如式(X)所示的噻吩并[2,3-d]嘧啶基，即：
Ar1和Ar2中的另一个为未取代的芳烃基或取代的芳烃基、或者杂芳基；这里，所述未取代的芳烃基为苯基，所述取代的芳烃基为取代的苯基；所述取代的苯基是指苯环被一个或两个以上的如下基团所取代：C1-4烷基、卤代C1-4烷基、C1-4烷氧基、C1-4烷氧羰酰基、羟基、卤素、氨基、单C1-4烷基取代的氨基、双C1-4烷基取代的氨基、硝基和氰基，或者苯环上相邻的两个碳和与其相连的杂原子、亚烷基一起形成5元或6元杂环，其中杂原子为氮或氧且杂原子个数为2个；所述杂芳基为噻吩基、呋喃基、或吡啶基；
式(X)中取代基R1和R2各自独立地选自氢或者C1-C4烷基。
2.根据权利要求1所述的查耳酮类似物，其中，式(I)中R1为甲基，R2为氢。
3.根据权利要求1所述的查耳酮类似物，其中，式(I)为下列式(II)化合物：
其中，式(II)中Ar2、R1和R2的定义如权利要求1式(I)化合物。
4.根据权利要求1所述的查耳酮类似物，其中，式(I)为下列式(III)化合物：
其中，式(III)中Ar1、R1和R2的定义如权利要求1式(I)化合物。
5.根据权利要求1至4中任一项所述的查耳酮类似物，其中，所述取代的苯基为4-甲基苯基、4-甲氧基苯基、4-硝基苯基、4-溴代苯基、4-氯代苯基、4-氟代苯基、2,4-二甲氧基苯基、4-羟基-3-甲氧基苯基、2,4,6-三甲氧基苯基、或3,4,5-三甲氧基苯基。
6.根据权利要求1至4中任一项所述的查耳酮类似物，其中，所述杂芳基为噻吩-2-基、呋喃-2-基、吡啶-2-基、吡啶-3-基、或吡啶-4-基。
7.如权利要求1所述的查耳酮类似物，选自如下化合物中的一种：
(E)-6-甲基-2-(3-苯基丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-(4-甲氧基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-(2,4-二甲氧基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-(2,4,6-三甲氧基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-(3,4,5-三甲氧基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-(4-羟基-3-甲氧基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-(4-甲基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-(4-溴苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-(4-氯苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-(4-氟苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-(4-硝基苯基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-(呋喃-2-基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-(噻吩-2-基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-(吡啶-2-基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-(吡啶-3-基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-(吡啶-4-基)丙烯酰)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-氧代-3-苯基丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-氧代-3-(4-甲氧基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-氧代-3-(2,4-二甲氧基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-氧代-3-(2,4,6-三甲氧基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-氧代-3-(3,4,5-三甲氧基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-氧代-3-(4-羟基-3-甲氧基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-氧代-3-(4-甲基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-氧代-3-(4-溴苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-氧代-3-(4-氯苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-氧代-3-(4-氟苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-氧代-3-(4-硝基苯基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-氧代-3-(呋喃-2-基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-氧代-3-(噻吩-2-基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-氧代-3-(吡啶-2-基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮；
(E)-6-甲基-2-(3-氧代-3-(吡啶-3-基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮；和
(E)-6-甲基-2-(3-氧代-3-(吡啶-4-基)丙-1-烯-1-基)噻吩并[2,3-d]嘧啶-4(3H)-酮。
8.一种包含权利要求1至7中任一权利要求所述查耳酮类似物的药用组合物。
9.如权利要求1至7中任一权利要求所述的查耳酮类似物或如权利要求8所述的药用组合物在制备抗肿瘤药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910925935.3A CN110590806B (zh) | 2019-09-27 | 2019-09-27 | 含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物及其制备方法和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910925935.3A CN110590806B (zh) | 2019-09-27 | 2019-09-27 | 含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110590806A CN110590806A (zh) | 2019-12-20 |
| CN110590806B true CN110590806B (zh) | 2021-10-29 |
Family
ID=68864263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910925935.3A Active CN110590806B (zh) | 2019-09-27 | 2019-09-27 | 含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物及其制备方法和用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110590806B (zh) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011237642B2 (en) * | 2010-04-06 | 2014-05-01 | Brigham Young University | Antimetastatic compounds |
| CN104803927B (zh) * | 2015-03-31 | 2017-11-07 | 首都师范大学 | 含2‑甲基‑4‑氧代喹唑啉‑6‑基的查耳酮类似物及其制备方法和用途 |
| CN105503745B (zh) * | 2016-01-07 | 2018-10-19 | 首都师范大学 | 含4-氧代喹唑啉-2-基的查耳酮类似物及其制备方法和用途 |
-
2019
- 2019-09-27 CN CN201910925935.3A patent/CN110590806B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN110590806A (zh) | 2019-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1444228B1 (en) | Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors | |
| EP2001890B1 (en) | Tetrahydropyridothienopyrimidine compounds and use for the treatment of cell proliferative disorders | |
| CN1968929B (zh) | 取代的四氢-2h-异喹啉-1-酮衍生物、其制备方法以及其作为药物的用途 | |
| Abdelazeem et al. | Design, synthesis and biological evaluation of novel diphenylthiazole-based cyclooxygenase inhibitors as potential anticancer agents | |
| KR101067551B1 (ko) | Ａｋｔ(단백질 키나제 ｂ)의 억제제 | |
| CZ400992A3 (en) | Quinazoline derivatives for enhancing anti-tumor activity | |
| CN101605780A (zh) | 新型n,n’-2,4-二苯胺基嘧啶衍生物、其作为药物的制备、药物组合物和尤其作为ikk抑制剂的用途 | |
| Kamal et al. | Synthesis of 4β-carbamoyl epipodophyllotoxins as potential antitumour agents | |
| JP5778145B2 (ja) | 抗癌剤としてのベンゾキノリジニウム塩誘導体 | |
| WO2013178021A1 (zh) | 吡咯并[2，1—f][1，2，4]三嗪衍生物及其抗肿瘤用途 | |
| RU2129546C1 (ru) | 6,9-бис(аминозамещенные)-бензо(g)изохинолин-5,10-дионы, способ их получения, фармацевтическая композиция на их основе и способ ингибирования опухолей у млекопитающих | |
| US20220227720A1 (en) | Dhodh inhibitors and their use as antiviral agents | |
| Li et al. | Molecular design, chemical synthesis, and biological evaluation of ‘4-1’pentacyclic aryl/heteroaryl-imidazonaphthalimides | |
| CN108503623A (zh) | 一种抑制prmt7的化合物及其制备方法与应用 | |
| CN106673988B (zh) | 苄亚基环己烯酮衍生物及其制备方法和医药用途 | |
| CN106946868B (zh) | 一氧化氮供体型香豆素衍生物、其制备方法及医药用途 | |
| CN110590806B (zh) | 含噻吩并[2,3-d]嘧啶-2-基的查耳酮类似物及其制备方法和用途 | |
| Liu et al. | Synthesis and anti-hepatitis B virus evaluation of novel ethyl 6-hydroxyquinoline-3-carboxylates in vitro | |
| CN113166148B (zh) | 作为cdk-hdac双通路抑制剂的杂环化合物 | |
| CN112250688A (zh) | 一类7-氮杂苯并呋喃衍生物及其在抗肿瘤药物中的应用 | |
| CN105503745B (zh) | 含4-氧代喹唑啉-2-基的查耳酮类似物及其制备方法和用途 | |
| CN104211712B (zh) | 含杂芳基哌啶的青蒿素衍生物、其制备方法及应用 | |
| Lougiakis et al. | Synthesis, cytotoxic activity evaluation and mechanistic investigation of novel 3, 7-diarylsubstituted 6-azaindoles | |
| KR100566194B1 (ko) | 신규의 3-니트로피리딘 유도체 및 그를 포함하는 약학적조성물 | |
| WO2009152584A1 (en) | Synthesis of ageladine a and analogs thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |